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Abstract 
 
 Azetidine is a four-membered nitrogen-containing heterocyclic ring that has 
recently received a great deal of attention as a molecular scaffold for the design and 
preparation of biologically active compounds. Structure-activity studies employing 
functionalized azetidines have led to the development of a variety of drug molecules and 
clinical candidates encompassing a broad spectrum of biological activities.  
Herein, the synthesis of a novel series of 3-aryl-3-arylmethoxyazetidines is 
described. Selected 3-aryl-3-arylmethoxyazetidines were evaluated for their binding 
affinity to multiple monoaminergic transporters for the potential treatment of 
methamphetamine addiction. It was discovered that this scaffold exhibits high binding 
affinity (nM) for both the serotonin and dopamine transporters. In addition, a new method 
was developed for the synthesis of 3,3-diarylazetidines. This new approach provides a 
facile and efficient method to synthesize a variety of diaryl heterocycles including 3,3-
diarylazetidines, 3,3-diarylpyrrolidines, and 4,4-diarylpiperidines in moderate to good 
yields. 
 
 
 
 
 
Key Words: Azetidines, Methamphetamine addiction, Multi-targeted monoaminergic 
reuptake inhibitor, Diaryl heterocycle, Friedel-Crafts alkylation   
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Part I: Synthesis and Biological Evaluation of  
3-Aryl-3-Arylmethoxy azetidines 
 
 
 
 
Abstract 
 
Methamphetamine (METH) is a highly addictive synthetic psychostimulant that 
targets monoaminergic transporters dopamine, serotonin, and norepinephrine located in 
the central nervous system. In an effort to find a single pharmacophore for the treatment of 
methamphetamine addiction, a series of novel of 3-aryl-3-arylmethoxyazetidine analogs as 
potential multi-targeted monoaminergic reuptake inhibitors have been synthesized and 
evaluated by in vivo studies. These analogs were found to be active (nM) for the 
serotonergic transporter and dopaminergic transporter in rat brain tissue. The aim of the 
project is to find a dually active compound at both the serotonin (SERT) and dopamine 
(DAT) transporters, which could be used in the field of psychotherapeutics. Binding studies 
for serotoninergic and dopaminergic transporters were completed by competitive 
inhibition against [3H]citalopram and [3H]WIN 35,428 , respectively, in rat brain tissue.  
The scaffold proved to be highly selective for the serotonin receptor with N-methyl-
3-phenyl-3-(3,4-dichlorophenylmethoxy)azetidine  (31c) exhibiting high potency and 
 2 
selectivity for the serotonin transporter over the dopamine transporter (Ki = 1.0 nM, Ki = 
1210 nM respectively). Analog N-methyl-3-(3,4-dichlorophenyl)-3-
phenylmethoxyazetidine (31g) exhibited the highest dopamine binding affinity (Ki = 620 
nM) while maintaining good serotonin binding affinity (Ki = 23.2nM) which offered a 
moderate serotoninergic/dopaminergic selectivity of 27. The 3-aryl-3-
arylmethoxyazetidine scaffold proved to be a tunable template where minor changes in 
substitution on the aryl moieties as well as substitution at nitrogen on the azetidine ring 
can dramatically modify binding affinities and selectivity for multiple monoaminergic 
transporters. 
 
Key Words: Azetidines, Methamphetamine addiction, Multi-targeted monoaminergic 
reuptake inhibitor.  
 
  
 3 
Introduction 
 
1.1 History of Methamphetamine 
 
Methamphetamine, N-methyl-1-phenylpropan-2-amine (1), was originally 
synthesized by Japanese chemist and pharmacologist Nagia Nagayoshi during his studies 
on naturally occurring ephedrine (2).1  
 
 
 
Nagia was a well-respected chemist and member of the Meiji Japanese elite. He 
devoted most of his time to the chemical analysis of traditional Japanese and Chinese 
medicines utilizing the instruments and techniques of Western science. In 1885, Nagai 
isolated ephedrine from Ephedra sinica, a plant used for centuries in Chinese medicine. 
Ephedra, or ma huang as it is known in Chinese medicine, was typically brewed into teas 
and used for its effects of increased blood circulation, and reduction of coughs and fever.2   
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In July 1884, Sigmund Freud published his highly popular accolade to the wonders 
of cocaine, Über Coca. Cocaine exhibited effects profoundly more potent than its parent 
coca leaves, and chemists around the world were on the lookout for the next potential 
wonder drug.3 It is probable that Nagai hoped extracts from Ephedra would be the next big 
hit – and in many ways it was. Ephedrine was first synthesized in 1920, and the structure 
identified. It was during those synthetic trials that methamphetamine (METH) was 
created.2  
METH was introduced to the American market in 1932 by the company Smith Klein 
and French as the “Over-the-counter” (OTC) bronchodilator, Benzedrine, for the treatment 
of asthma. By 1937 the American Medical Association allowed for a tablet form of the drug 
to be prescribed for the treatment of narcolepsy.4 In both the tablet and inhaler form, 
Benzedrine was sold as the racemic mixture of methamphetamine. 
During the United States federal government ban on the possession and distribution 
of alcohol (1920-1933), METH and other now controlled substances then found in OTC 
drugs thrived. The Benzedrine inhaler alone contained the equivalent of approximately 56 
METH tablets and, was readily available to people even with no known illnesses. The start 
of the Great Depression (1929-1939) combined with prohibition had many Americans 
turning to medicinal sources for pleasure.  It was reported that the nasal strips from the 
Benzedrine inhalers were removed and stirred in morning coffee to bring a small sense of 
happiness in the desolate times.4 During this time, “pep-pills,” such as Benzedrine, were 
legal and openly distributed everywhere from student unions to truck stops and few 
 5 
thought much about the side effects and long term consequences of chronic 
methamphetamine use.4   
The end to the Great Depression was greeted with the start of the second major 
world war. Though American prohibition was over, methamphetamine actually increased 
in popularity, which was aided, in part, by the United States government. Due to the short-
term benefits of METH use, such as increased alertness and activity, increased aggression, 
and decreased appetite and fatigue, the United States military as well as the military forces 
of Germany, and Japan readily distributed METH to soldiers during the war. The US 
military alone circulated an estimated 200 million METH tablets to its troops.4 At the time, 
the toxicology and long-term effects of METH were not known.1 In addition to METH 
distribution to soldiers, it has been established that Adolph Hitler was a strong advocate 
and frequent METH user. By October 1942 he received daily injections of increasing doses 
of a drug cocktail containing METH.4 
After World War II, soldiers and civilians continued using methamphetamine. METH 
was available in an injectable form at the time, and became a unique recreational drug.1 
The impact of METH use can be seen in the work of many artists and writers of the day. 
This is most evident in Jack Kerouac’s novel On the Road. Kerouac claimed he wrote the 
novel on a 20 day Benzedrine high.4 His “free-form” literature became a hallmark of the 
entire Beatnik culture that reflected a free-form lifestyle of the more broadly based hippie 
movement in the 1960s and 1970s.4  
By the mid 1960s it became increasingly difficult to get a prescription for injectable 
METH by simply claiming to be afflicted by any ailment. This is because physicians began 
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noticing negative side effects in long-term METH users, including an addiction pattern and 
a severe decline in dental health.4 In response to the lack of readily available METH 
prescriptions, clandestine labs illegally manufacturing METH began popping up around the 
San Francisco and San Diego areas of California.5 By 1968 an estimated 5-10 large scale 
labs and an unknown number of “mom and pop” operations were well established in the 
San Francisco Bay area.5 These labs were aided in transportation and distribution of METH 
by famous west coast motorcycle gangs such as the Hell’s Angels. METH was stored and 
transported in the crankcase of motorcycles, where it earned the street name “crank”.1  
In an effort to combat the addictive long-term effects of many drugs new legislation 
was generated. The 91st congress passed the Comprehensive Drug Abuse Prevention and 
Control Act of 1970, which was signed into law by President Nixon. It was under this act 
that made the manufacturing, possession, distribution and importation of certain drugs 
illegal.6 Under new legislation, METH became a Schedule II drug and only legally available 
by prescription under extreme circumstance.6 This law only led to an increase in the 
number of clandestine labs and illegal production of METH.1 
In the 1980s the freebase smoke-able crystalline form of METH called “Ice” became 
popular due to its fast acting, and long lasting effects.1,4 “Ice” is said to provide a high 
lasting anywhere from eight to twenty-four hours, and the user is exceptionally violent, 
paranoid, and suffers from auditory and visual hallucinations.4 This may be due to Ice being 
the pure dextro enantiomer versus the enantiomeric mixtures seen in the liquid form. The 
dextro enantiomer is two to four times as stimulating as its levo counterpart, which is more 
commonly ingested nasally, orally or injected.4 The crystalline METH was imported from 
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Asia and Hawaii and quickly made its way east.1 In addition to being more potent than 
racemic METH, “Ice” was also very attractive because it was easy to transport, and had a 
new smoke-able form of ingestion. “Ice” quickly gained popularity with users and 
clandestine lab manufacturers and became the standard form of METH produced and 
used.5 
Though the Comprehensive Drug Abuse Prevention and Control Act of 1970 made 
the possession of intermediates and starting materials of METH illegal, new methods for 
production were created using common household ingredients.4 These methods were 
published in a 1987 book entitled Secrets of Methamphetamine Manufacture written under 
the pseudonym Uncle Fester.5  
From the late 1980’s to today, METH use has not been forgotten.  With the booming 
US population METH use has spread. Today METH can be almost odorously synthesized in 
homes across America using a stovetop or even soda bottles.4-7 According to the United 
States Drug Enforcement Agency over 80% of clandestine lab seizures are METH labs due 
to the ease of methamphetamine synthesis. These issues brought forth the 
Methamphetamine Control Act of 1996, which controlled drug products containing the 
known METH starting materials ephedrine (2), pseudoephedrine (3) and phenyl-2-
propanone (4). This law put a limit on the amount of OTC drugs containing these METH 
precursors one can purchase at a time.4  
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A 2012 study completed by the National Survey on Drug Use and Heath (NSDUH) 
found that over 12 million Americans have tried METH in their life time with 133,000 
reported new users within that year.6 METH is ranked second in popularity for abused 
substances among the United States youth falling well behind marijuana as the most 
popular abused substance.8 Though heavy METH use originated on the west coast, today, 
the highest concentration of METH users are in the Midwestern United States with the top 
five highest METH using states being Missouri, Kentucky, Indiana, Oklahoma, and Illinois.9 
METH is highly addictive, with an estimated 98% of first time triers become users 
after the first time. Even if they are not addicted after their first experience with METH an 
estimated 90% of users become abusers within one year of initial intake.10 
Methamphetamine users become physically dependent on the drug, quickly developing a 
tolerance which forces the user to increase dosage to achieve the same effects.   
METH abusers will do anything to get their next hit and according to law 
enforcement, METH is considered “a drug so harmful and damaging that it has been blamed 
for the destruction of the social fabric of many large areas across the United States”.10 
METH has long lasting psychological and physiological effects that are harmful to not only 
the user but also those around them. Crimes are increasing as a direct result of METH use. 
 9 
Responding officials in Illinois say that 70% burglaries have increased because of METH 
use over the last year.11  
A related survey conducted in Illinois found that METH is a key source of child abuse 
and neglect, and 40% of all child welfare officials reported increased out-of-home 
placements of children due to parental METH use over the past year. An approximate 59% 
of child welfare officials also reported that when parents are addicted to METH, it increases 
the difficulty of family reunification efforts.11 
 
1.2 Effects of Meth  
 
The short term effects of METH have been sought out by a variety of people from 
housewives, truck drivers, students and soldiers.1,4-5 Because METH is a powerful stimulant 
small doses can provide positive effects of increased wakefulness, increased physical 
activity, increased attention and decreased appetite, all coupled with euphoria and a boost 
in confidence. However the user could also experience increased respiration, rapid or 
irregular heartbeat and hyperthermia.4,6-7,12 However, it is the long-term effects that have 
the most damage on the body. Immediate euphoria upon administration leads to addiction. 
This addiction typically leads to a gradual dosage and/or frequency increase to create the 
same effect. Chronic METH abusers may develop difficulty feeling any pleasure other than 
that provided by the drug, thus fueling the abuse. In addition, chronic users may exhibit 
increased distractibility, memory loss, aggression or violent behavior, weight loss, and 
psychosis including paranoia, hallucinations, and repetitive motor activity.6,7,12  
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 Withdrawal symptoms are not acute and may take upwards of 90 days to be 
expressed by an addicted individual. These symptoms can include depression, cravings, 
lack of energy and even suicidal thoughts.  Research suggests that brain abnormalities 
similar to those seen in depression and/or anxiety patents can occur when a person 
discontinues METH use. METH abuse has an extremely high relapse rate of more than 90% 
of individuals returning to use.12  
 
1.3 Monoamine Neurotransporters 
There are three main monoamines found in the CNS: dopamine, serotonin, and 
norepinephrine. Dopamine (5) governs pleasure and reward systems, whereas serotonin 
(6) regulates well-being and happiness, and norepinephrine (7) modulates concentration 
and attention.7 These emotions are expressed when a high concentration of the monoamine 
is present at their respective transporter synaptic cleft. For example, reaching a personal 
goal would initiate release of dopamine and provide the pleasurable feeling of a job well 
done.4    
 
 
 11
Each of these monoamines is transmitted through the CNS by their respective 
neurotransporters. These neurotransporter systems belong to the sodium symporter (NSS) 
family of transporters which regulate monoamine concentrations at the neuronal synaptic 
cleft by carrying them across neuronal membranes into presynaptic nerve cells as seen in 
Figure 1.13-14 
 
 
Figure 1: Transportation of dopamine at a dopamine transporter synaptic cleft14 
 
 
Together, monoamine transporters are responsible for mood modulation. Modifying 
the concentration of any of these monoamines can disrupt the delicate balance each of 
these systems play and drastically modify behaviors.  
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1.4 Effects of METH on Neurotransporters 
 
The interaction of methamphetamine with the dopaminergic system is the most 
widely studied and well known. As seen in Figure 2, METH acts on this system in several 
ways to flood the synapse with high concentrations of dopamine, thus giving the user a 
rush of euphoria and an activation of the reward system.15 METH first permeates the 
dopamine containing axon of the neurotransmitter, binds to the stored dopamine 
containing vesicles forcing the release of excess dopamine into the synaptic cleft. It also 
competitively binds to the dopamine reuptake transporter and blocks the natural reuptake 
of dopamine. This creates a flood of dopamine at the synapse, which initiates the 
pleasurable sensation attributed to illicit drugs.16 
 
 
Figure 2: Effects of METH on dopamine transporter15 
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Post-mortem studies of METH abusers have shown that dopamine levels in the striatum 
were severely depleted, indicating that METH can cause a release of dopamine large 
enough to completely exhaust stores in the tissue.17-18 There is also evidence of structural 
neuronal damage of long time METH users. Depleting stores of dopamine followed by 
neuronal damage may lead to decreased dopamine production.19  
A live study was completed which measured dopamine receptor levels, using a 
radioactive tag that binds to dopaminergic receptors in the brain. Subjects brains were 
then imaged using a positron emission tomography (PET) scan that visualizes the 
radioactive tag and shows where it is bound to receptors. The strength of the signal 
indicates the concentration of receptors.20 
 
 
Figure 3: PET scan evaluating dopamine levels of a healthy brain and a brain of a METH abuser20 
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As seen in Figure 3, methamphetamine abusers had significantly lower levels of 
dopaminergic receptors than the control subjects. And the lower the number of 
dopaminergic receptors, the lower the metabolic activity in the orbitofrontal cortex. The 
blunted orbitofrontal cortex activity in these drug abusers reduces the ability of all other 
stimuli to trigger a reward response making ordinary stimuli not strong enough to activate 
the transporters.20 
Though the mode of action is not as well known, serotonin is also released and 
observed concentrations are elevated. Studies have shown significant loss of serotonin 
concentrations in the cerebral cortical and subcortical regions of the brain in chronic METH 
users. There is evidence that serotonin transporter function is rapidly impaired upon 
METH administration.21-23 It was seen that multiple administrations of METH rapidly 
decreased serotonin transporter function in rat striatum and hippocampus. These 
injections rapidly decreased serotonin uptake without altering the binding of the 
serotonergic transporter ligand paroxetine.24 This decrease in serotonin sinks the addict 
into a depression which is the number one cause of relapse in recovering addicts.12    
 The noradrenergic transporter, while less vulnerable than dopaminergic and 
serotonergic transporters, demonstrates significant METH induced effects. A decrease in 
norepinephrine transporter activity observed is a direct effect of dopamine and serotonin 
depletion due to high METH use. Abusers who demonstrate METH induced psychosis have 
been shown to exhibit elevated norepinephrine levels.25  
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1.5 Methamphetamine vs Cocaine 
 
Cocaine is a plant-derived drug found in the Erythroxylon coca bush. It is another 
widely abused psychostimulant that is active at the dopamine transporter. However, 
cocaine acts solely as a re-uptake inhibitor, which competitively binds to the transporter to 
block the re-uptake of naturally occurring dopamine, (Figure 4), thus elevating dopamine 
concentrations.26-27 
 
Figure 4: Effect of cocaine on the dopamine transporter system27 
 
 
In contrast to METH, the body quickly metabolizes cocaine. Cocaine exhibits a half-life of an 
hour, whereas METH has a half-life of 12 hours.  
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1.6 Attempted Methamphetamine Medications 
 
 Behavioral treatment programs have had some success in the treatment of 
methamphetamine addiction, however, many patients relapse even after several attempted 
treatments.28 Therefore, several pharmacotherapies have been attempted to compliment 
behavioral treatment programs.  
The first pharmacotherapy program attempted utilized dextro-amphetamine. A 
preliminary study has demonstrated that a maintenance pharmacotherapy program of 
daily sustained-release dextro-amphetamine dispensed under pharmacist supervision is 
both feasible and safe. Clinical trial participants who received dextro-amphetamine in 
controlled conditions stayed in the program longer than those receiving a placebo.28 That 
coupled with a general decreases in methamphetamine use, degree of dependence and 
withdrawal symptom severity, provided preliminary evidence that this may be an 
efficacious treatment option for methamphetamine dependence.28 However, it due to the 
structural similarities between METH and dextro-amphetamine, medication self-
administration would probably not be feasible. It is probable that the methamphetamine 
abuser would simply begin abusing dextro-amphetamine instead of METH.  
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Attempts at utilizing dopaminergic selective re-uptake inhibitor bupropion, and 
serotonin selective re-uptake inhibitor fluoxetine independently showed reduce cravings of 
METH and improve adherence to treatment. However, both had minimal effects at reducing 
overall METH dependence.29-30  
Fluoxetine is a serotonin selective re-uptake inhibitor (SSRI) synthesized by Eli Lilly 
Company. It is commonly used for the treatment of depression, obsessive-compulsive 
disorder and panic disorder. Fluoxetine has been on the United States market since 
December 1987, and is the third most prescribed SSRI after sertraline and citalopram.31 A 
Cochrane review concluded that fluoxetine at a dosage of 40 mg per day may have modest 
benefits in reducing short-term methamphetamine craving but does not reduce 
methamphetamine use or abuse.32  
Bupropion is an abnormal antidepressant because it exhibits stimulant properties.33 
Bupropion is typically used for the treatment of depression and smoking cessation. The 
early clinical findings for the use of bupropion for methamphetamine addiction treatments 
were promising. For example, bupropion treatment (twice daily, 150 mg, sustained 
release) was well tolerated in patients that received intravenous METH infusions of 15 mg 
or 30 mg and by those abstaining from methamphetamine use. Additionally, bupropion 
reduced the subjective effects and cue-induced cravings of methamphetamine, and 
increased duration of abstinence in male participants classified as having “mild-to-
moderate” methamphetamine dependence. In vivo studies determined that acute 
administration of 30 and 60 mg/kg bupropion decreased intake of 0.025, 0.05, and 0.1 
mg/kg/infusion of methamphetamine.33 However, bupropion (30 mg/kg) only 
momentarily reduced methamphetamine intake suggesting decreased effectiveness for 
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long-term administration as would be expected in an addict treatment plan.33   
 
 
1.7 Dual Target Hypothesis 
 
It is evident that monoaminergic systems are responsible for modulation of 
METH-induced behaviors. However, dopaminergic and serotonergic selective medications 
have separately failed at reducing METH use among abusers.34-37 Available medications 
that have application to other abused substances such as cocaine fall short of being 
effective in treating the complex pharmacology of METH addiction. The failure of these 
drugs to be effective against METH is thought to be due to the limited scope of action: 
targeting single monoaminergic systems.  
To date there is mounting evidence that in addition to dopaminergic systems, brain 
serotonergic systems also modulate responses in methamphetamine-induced behaviors.38-
40 However, it has become evident that a single dopaminergic or serotonergic agent cannot 
adequately reduce the behavioral effects associated with psychostimulant abuse. Therefore, 
it has been suggested that a calibrated dual dopaminergic/serotonergic agent could be 
more effective.39-42  
A multi-targeted monoamine pharmacophore could be used to avoid psychotic 
effects and reduce reinforcing effects during METH detoxification. This theory is backed by 
several examples of weakened stimulant effects of dopaminergic agents by serotonergic 
activity, the most common being Fen-phen.42 Fen-phen was an anti-obesity treatment that 
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utilized two anorectics fenfluramine and phentermine. In this case, the stimulating effects 
of the dopaminergic/norepinephrine selective phentermine (8) are tempered by the 
serotonin releaser fenfluramine (9).42  
 
 
 
This model suggests that drug-induced dopamine and serotonin irregularities play a 
role in drug craving, withdrawal symptoms, and relapse.42-44 Therefore, is it is postulated 
that a medication to restore dopaminergic and serotonergic levels should be able to treat 
dopamine and serotonin deficient stimulant abusers. 
Previous studies of up-take inhibitor treatments for the treatment of the stimulant 
cocaine have utilized cocktails of dopaminergic selective and serotonergic selective 
inhibitors.45 This cocktail was given to rhesus monkeys and it was found that the 
combination was successful in preventing self-administration of cocaine. However, drug 
cocktails can be problematic due to pharmacokinetic differences between the medications. 
Formulating a single compound that could serve as a dual dopaminergic/serotonergic 
uptake inhibitor (DUI) or a dopaminergic/serotonergic/noradrenergic triple uptake 
inhibitor (TUI) could combat this issue and be used to restore monoaminergic levels and 
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reduce behavioral effects of METH.45 
Based on the pharmacological evidence available, it is clear that attenuation of 
dopaminergic, serotonergic and noradrenergic uptake can affect the behaviors associated 
with METH abuse and addiction. In addition, uptake inhibitors clearly offer a safer 
mechanism than releasing agents to attenuate METH activated monoaminergic systems. 
The failures of previous therapeutic approaches, we believe, has been due to the lack of a 
multi-target approach that addresses multiple transporter systems.  
 
1.8 Triple Re-uptake Inhibitors in Clinical Trials 
 
Currently there are multiple triple re-uptake inhibitors (TUIs) in clinical trials, none 
of which are explicitly intended for METH addiction. Euthymics Bioscience has two 
derivatives in clinical trials: Amitifadine® (10) and Nuerovance® (11).46-47 Amitifadine® 
has a 1:2:8 selectivity for SERT, NET and DAT respectively and is in clinical trials for major 
depression disorder (MDD).46,48-49 At the conclusion of its May 2013 trails a brief statement 
was made that Amitifadine® has shown “statistical significance for anti-depressant 
effects.”46 Nuerovance® is in clinical trials for adult attention deficit disorder (ADHD) and 
has a 1:6:14 SERT:DAT:NET selectivity ratio.47  
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Due to relative novelty not much is known about the MDD medications from 
Lundbeck and Takeda, 12, or Glaxo-Smith Klein, 13. However, across each molecule similar 
motifs are seen.50-51 Each compound contains a heterocyclic amine, and an electron rich 
aromatic group. Amitifadine®, Nurovance® and 13 have a rigid carbocyclic system.  
 
 
1.9 Ibudilast 
 
 MediciNova has a possible drug candidate for METH abuse, MN-166, which is 
currently in Phase II clinical trials.6,52,53 MN-166, dubbed Ibudilast, is the first non-opioid 
drug for the treatment of several pain indications and drug abuse treatment. Ibudilast (14) 
is a glial reducer that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6. It has 
also been shown to be a functional antagonist that may contribute to its attenuation of 
neuroinflammation.52 While Ibudilast is a new molecular entity in the US it has been 
prescribed on the Japanese markets for more than 20 years for treatment of asthma.54 
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According to the MediciNova website55, preclinical studies have shown that 
Ibudilast may prevent the activation of glial cells in the CNS that have been linked to drug 
dependence.55 In September 2012, University of California at Los Angeles’s Department of 
Family Medicine/Center for Behavioral and Addiction Medicine, and MediciNova, 
announced approval for the commencement of Phase II clinical trials investigating the use 
Ibudilast for the treatment of METH addiction.52 These trials, funded by the National 
Institute on Drug Abuse (NIDA), have had eleven reported volunteers to date which have 
passed safety tests and shown early signs of eased METH addiction. 52,56 Clinical trials are 
scheduled to conclude July 2017. 57 
 
 
1.10 Approach and Investigation of 3-Aryl-3-arylmethoxytropanes 
 
 Our approach to finding a pharmacophore for the treatment of METH addiction is 
innovative in that it seeks a single molecule to act as a re-uptake inhibitor at multiple 
neurotransmitters. This eliminates any issue of differentiated pharmacokinetics by 
multiple medications and is potentially less toxic than monoamine releasing agents. Our 
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efforts to develop a novel molecular scaffold began with the investigation of several classes 
of dopaminergic selective and serotonergic selective ligands.  
In a search for stimulant abuse a variety of compounds have been evaluated as 
dopamine re-uptake inhibitors. WIN-35,065-2 (15), methylphenidates (16), mazindols 
(17), benztropines (18), and GBR analogs (19) are a representative collection of those 
compounds, which have a high affinity for the dopamine transporter.  
 
 
 
 
In the search for a cocaine abuse drug, extensive studies were completed by the 
Clark group on the 3-phenyltropane scaffold. WIN-35,065-2 (IC50 = 23nM) was found to be 
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four times more potent than cocaine (IC50 = 89nM) at the dopaminergic transporter.58 This 
provided a new scaffold for investigation at the dopamine transporter.59 Structure activity 
relationship studies on 3-phenyltropanes examined substitution at the 4-position of the 
aryl moiety. It was determined that this position plays a critical role in enhancing 
dopamine transporter affinity and substitution there resulted in analogs that exhibited 
high to moderate affinity (Ki < 2 nM to 200nM) at the dopamine transporter.60 An 
interesting feature of these analogues was that they were much more selective for the 
serotonin transporter than the dopamine and norepinephrine transporters.61 
Substitutions at the 3-positon of the aryl moiety of WIN 35,065-2 were also 
synthesized and analyzed for their binding affinities. However, it was determined 3-
substitution does not affect the dopamine transporter binding affinity as significantly as 
substitution at the 4-position. Addition of halogens (F, Cl, Br, I), and phenyl groups at the 3-
position only produced analogues which were only four to nine times more potent than 
cocaine.42-63 Disubstitution at the 3, 4-positions on the aryl provided some of the most 
potent 3-phenyltropanes to date.64 Combinations of -chloro, -fluoro, -bromo, or –iodo 
substituents at the 3,4-positions of the phenyl group provided compounds with 
subnanomolar affinities at the dopamine transporter (Ki  < 2nM).65 
Although halogens are well tolerated at the dopamine transporter, there is a limited 
tolerance for the hydroxyl group. Monohydroxyl substitution on the phenyl at 3- and 4- 
positions displayed dopamine transporter binding affinities around Ki = 12 nM whereas the 
3,4-dihydroxy analog was found to be 113-fold less potent at the dopamine transporter.66 
The catechol derivative was prepared to determine if the aryl group of phenyltropanes 
interacted with the dopamine transporter in a similar manner as the 3, 4-dihydroxylphenyl 
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group of dopamine. The low binding affinity of the dihydroxy-substituted tropane suggests 
that dopamine does not occupy the same binding site on the dopamine transporter as the 
3-phenyltropanes. 
A series of 2β-derivatives were synthesized and found, to have highly increased 
dopaminergic potency. Although in general, these compounds displayed high potencies and 
selectivities for the dopamine transporter, some compounds appear to have unique 
pharmacological profiles in vivo. Heterocyclic 2β-derivatives do not produce locomotor 
stimulation in mice despite having potent IC50 values at the dopamine transporter. This 
trend has also been observed for other classes of dopamine transporter uptake inhibitors 
and requires further investigation.67  
Exchanging the methyl group on the tropane nitrogen with alkyl, allyl and even 
phenylpropyl substitutions showed little effect on dopamine transporter binding affinity.68-
70 N-Substituted derivatives retained high affinity at the dopamine transporter and even 
analogues with bulky groups were well tolerated.68-69 
A large number of 3-phenyltropanes have been synthesized and analyzed for the 
purpose of selectively modulating the dopamine transporter for potential medications. 
Analogues have been developed with high affinity for all three transporters and many of 
these have been evaluated in locomotor activity and cocaine discrimination studies. Almost 
all the compounds investigated show reduction of cocaine self-administration in both rat 
and monkey models and some analogues are in clinical or advanced preclinical studies for 
treating cocaine addiction. 71-73 
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Serotonin selective re-uptake inhibitors (SSRIs) are commonly used medications. 
SSRIs are generally prescribed for treatment of depression under trade names of Paxil® 
(23) and Prozac® (20). The compounds below are illustrations of known SSRIs.  
 
 
 
 
 
Meperidine (22) is an atypical μ-opioid receptor agonist. Chronic use can produce 
central nervous system stimulant effects of hyperflexia and increased susceptibility to 
startle.74 These effects are generally specific to meperidine and are typically not observed 
with other μ-opioid receptor agonists such as morphine. Meperidine shares numerous 
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structural features with the 3-phenyltropane analogs.75 The piperidine ring is a common 
ring structure in both meperidine and the 3-phenyltropane. N-methyl substitution occurs 
in meperidine as well. The phenyl ring attached to the 3-position on the tropanes ring of 
the WIN 35065-2 is equivalent to the phenyl on the 4-position of the piperidine ring of 
meperidine. These common structural features between meperidine and cocaine congeners, 
such as WIN 35065-2, combined with the unique pharmacological profile of meperidine 
suggested that the non-opioid actions of meperidine could be due to a cocaine-like 
pharmacological action.74-76 
 
Given the similar structural characteristics of 3-phenyltropane and meperidine it 
was of interest to explore the possibility of merging the two pharmacophores to develop a 
class of monoamine transporter ligands that would have a unique profile of multiple 
transporter affinity as seen in Figure 5. To this end, the 3α-arylmethoxy-3β-aryltropane 
pharmacophore (25) was envisaged.77 
 
 
 
Figure 5: Approach to Pharmacophore Scaffold 
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Pharmacophore 25 was designed not only to incorporate the main skeletal features 
of the dopamine transporter selective 3-phenyltropane and the serotonin transporter 
selective meperidine, but the arylmethoxy moiety common to many of the prototypical 
serotonin selective re-uptake inhibitors (SSRIs) and serotonin-norepinephrine selective re-
uptake inhibitors (SNRIs) was also envisaged to be an important structural feature for 
molecular recognition at monoamine transporters.57  
Analogs of 3-methoxy-3-arylmethoxytopanes were synthesized and a structure-
activity relationship (SAR) was completed. These analogs were shown to possess 
nanomolar  (nM) affinity for both dopaminergic and serotonergic transporters but were 
generally selective for the serotonin transporter. Table 1 shows binding affinities for 3-
aryl-3-arylmethoxytopane analogs. The most potent serotonin transporter and dopamine 
transporter analog of the series was 25e with Ki = 0.061nM, and Ki = 16nM respectively.78 
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Table 1: Monoamine Transporter Affinity and Selectivity of 3-Aryl-3-arylmethoxytropanes 
 
Cpda Code R X Y 
DAT 
(Ki, nM)b 
SERT 
(Ki, nM) b 
NET 
(Ki, nM) b 
25a HK2-151 H H H 117 ± 19 247 ± 27 NT 
25b HK3-27 CH3 H H 95 ± 21 141 ± 7.0 446 ± 57 
25c HK6-63 H H F 2,137 ± 252 17 ± 6.0 NT 
25d HK3-77 H H Cl 22 ± 8 6.1 ± 0.5 101  ± 0 
25e HK3-45 H H 3,4-Cl2 16 ± 1 0.061 ± 0.024 996 ± 53 
25f HK3-87 H Cl H 172 ± 70 65 ± 25 1,718 ± 18 
25g HK3-19 H F F 105 ± 1 7.9 ± 3.7 1,443 ± 5 
25h HK3-35 H Cl Cl 63 ± 7 0.10 ± 0.02 2,370 ± 367 
25i HK3-119 H 3,4-Cl2 H 716 ± 52 62 ± 15 1,232 ± 438 
25j HK3-49 H 3,4-Cl2 3,4-Cl2 2,930 ± 70 4.7 ± 0.3 2,552 ± 326 
25k HK3-31 CH3 CF3 CF3 3,761 ± 632 7.4 ± 3.2 11,721 ± 3247 
aAll compounds were tested as the oxalate salts. bAll values are the mean ± SEM of three 
experiments performed in triplicate.  
 
 
 It is evident from Table 1 that changing substituents on aryl rings of the 3-aryl-3-
arylmethoxytropane scaffold can readily modify dopaminergic, serotonergic and 
noradrenergic binding affinity.78 Because the 3-aryl-3-arylmethoxytropane derivatives 
seen have exhibited high binding affinity and selectivity for the serotonin transporter, 
structural modifications seen in Figure 6 indicates enhanced affinities for dopaminergic 
and noradrenergic transporters.78  
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Figure 6: Modification areas for increased binding affinities 
 
 
1.11 Design Strategy for Novel 3-aryl-3-arylmethoxyazetidines 
 
It was discovered however that the 3-aryl-3-arylmethoxytropane scaffold had a high 
clogP, which could indicate that it is too lipophilic and could have poor bioavailability. It 
was envisaged that a less lipophilic scaffold could produce compounds with improved 
bioavailability and the azetidine derivative (26) was identified as a viable target scaffold.77 
The azetidine scaffold allows for lower molecular weight and less lipophilic (cLogP) 
analogs.  
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Lipophilicity values for un-substituted free-base for 3-phenyl-3-
pheylmethoxytropane and 3-penyl-3-phenylmethoxyazetidine were calculated using 
software from Collaborative Drug Discovery, Inc., and were found to be 3.67 and 3.02 
respectively.  These values increase for varying substitution on the α-aryl, β-aryl, and 
substitution at the amine.77 
The azetidine scaffold was validated computationally by the superposition of the un-
substituted 3-phenyl-3-phenylmethoxytropane (25) and 3-phenyl-3-
phenylmethoxazetidine (26) seen in Figure 7.77 This demonstrates that the azetidine 
scaffold allows for favorable alignment of the major structural elements of the two 
compounds. 
 Figure 7: Superimposed predicted favorable solvated conformers of 
 
 
 The retrosynthetic analysis for the synthesis of 3
outlined in Scheme 1. The synthesis was envisaged to start from the commercially 
available 1-Boc-3-azetidinone (
using lithium reagents and halogenated aryls to form the 
aryl-3-arylmethoxyazetine (29
protective group can then either be removed under acidic condi
secondary amine (30) or reduced with lithium aluminum hydride to form 
3-arylmethoxyazetidine (31).77
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Scheme 1: Retrosynthetic analysis for the preparation of 3-aryl-3-arylmethoxyazetidines 
 
 
 It has been established by the previously reported tropane structure-activity 
relationship studies that chloro and fluoro substitution on both the aryl and arylmethoxy 
substituents increased dopamine and norepinephrine transporter binding affinity. Methyl 
substitution on the amine, similar to that seen in both cocaine and methamphetamine, have 
markedly increased dopaminergic-binding affinity. In accordance with this data, 
substitution of chloro, fluoro and trifluoromethane at various positions on the aryl moieties 
on the azetidine scaffold can be examined for binding affinities at multiple monoaminergic 
systems.78-79 
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Results and Discussion 
 
2.1 Synthesis of 3-Aryl-3-arylmethoxyazetidine and N-Methyl-3-aryl-3-
arylmethoxyazetidine 
 
Due to the fragile nature of the azetidine ring, there were many obstacles 
encountered during development of synthesis. Several variations were attempted for each 
step of the full synthesis to determine the highest yielding results.  
 
2.1.1 Synthesis of N-Boc-3-aryl-3-azetidinol 
 
The first step of the synthetic approach was to convert commercially available 
reagents N-Boc-3-azetidinone (27) into N-Boc-3-phenyl-3-azetidinol (32). This was 
completed by reacting N-Boc-3-azetidinone with 1.8M phenyllithium in tetrahydrofuran 
(THF) solution at -78 oC overnight. Various equivalents of phenyl lithium solution were 
added to optimize yields. The reaction was also attempted in two different solvent systems, 
dichloromethane and tetrahydrofuran.86-87 It was discovered that three equivalents of 
lithium reagent and tetrahydrofuran as the solvent system gave the highest yielding 
reactions of 94%.   
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Scheme 2: Formation of N-Boc-3-phenyl-3-azetidinol 
 
 
Reactions with less than three equivalents of lithium reagent produced products in 
poor yield (26-31%), while reactions utilizing dichloromethane as a solvent system 
decomposed completely. Reacting N-Boc-3-azetidinone with higher than three equivalents 
of phenyl lithium solution did neither improve nor hinder results (four equivalents yielded 
80% product), but due to the expense of the chemical, using the reagent in excess of three 
equivalents was not warranted.              
Substituted N-Boc-3-aryl-3-azetidinols were synthesized in a similar fashion using 
the same solvent system and lithium reagent equivalencies as seen above. However, 
substituted aryls were first reacted with 2M butyllithium solution in hexanes before N-Boc-
3-azetidinone was added. This allowed for formation of an aryllithium intermediate (33), 
which then would react with N-Boc-3-azetidinone.  
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Scheme 3: Formation of substituted N-Boc-3-aryl-3-azetidinols 
 
 With this synthesis, a variety of substituted 3-aryl-azetidinol analogs could be 
synthesized. Compounds 34a-h were synthesized using the optimized reaction conditions.  
 
 
Figure 8: N-Boc-3-aryl-3-azetidinol derivatives 
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2.1.2  Synthesis of N-Boc-3-aryl-3-arylmethoxyazetidine 
 
Benzylation of the tertiary azetidinol (28) was also attempted under a variety of 
reaction conditions. First by reacting N-boc-3-aryl-3-azetidinol with 1.5 equivalents of 60% 
sodium hydride in N,N-Dimethylformamide followed by 5 equivalents of halogenated 
benzyl bromide under inert conditions.83 However, the results varied from 10-75% yield. 
When a catalytic amount of sodium iodide was added to the reaction, a slight increase in 
percent yield (from 10% to 35%) was seen.  
 
 
Scheme 4: Attempted formation of N-Boc-3-aryl-3-arylmethoxyazetidine 
 
 
Another issue seen with this procedure was that not all of the starting material was 
reacting. This created a need for column chromatography. This was completed using 30% 
ethyl acetate/hexanes. However, decomposition of the intended product occurred while on 
the column. Assuming that the column was too acidic, 1% NH4OH was added to the solvent 
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system. This worked for both the benzyloxy and 3,4-dichlorobezyloxy compounds but 
some decomposition was still seen for the 4-chlorobenzyloxy series.  
Therefore, a simpler two-phase reaction was implemented. 1-Boc-3-phenyl-3-
azetidinol and a catalytic amount of tetrabutylammonium bromide were dissolved in 
dichloromethane and freshly prepared 4N sodium hydroxide solution. The corresponding 
benzyl bromide was added and the reaction refluxed at 35 °C overnight.77  
 
 
Scheme 5: Formation of N-Boc-3-aryl-3-arylmethoxyazetidine 
 
 
Once a procedure was determined optimization of the reagents was completed. It 
was determined that three equivalents of benzylbromide was sufficient for complete 
conversion of N-Boc-3-aryl-3-azetidinol to N-Boc-3-aryl-3-arylmethxoyazetidine. 
This procedure was mild, with quantitative results after column chromatography. 
Side products of this reaction identified by 1H NMR were excess benzyl bromide and 
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corresponding benzyl alcohol. With no unreacted azetidinol observed, the need for column 
chromatography was eliminated. All azetidinols were reacted with benzylbromide to give 
compounds 35a-h seen in Figure 9. 
 
 
Figure 9: 3-Aryl-3-phenylmethoxy analogs 
 
 
Substitution on benzylbromide in the form of 4-halo or 3,4-dihalobenzylbromide 
allows for numerous analogs to be synthesized. Compounds 36a-m (Figure 10) were 
synthesized using 4-choro, 4-fluoro 2-fluoro or 4-trifluoromethane benzylbromide. 
Compounds 37a-n (Figure 11) were synthesized 3,4-dichloro, 3,4-difluoro, 2,4-
bis(trifluoromethane) or 3,5-bis(trifluoromethane).  
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Figure 10: Substituted benzyl ether azetidine analogs 
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Figure 11: Di-substituted benzyl ether azetidine analogs 
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2.1.3 Optimization for Formation of N-Methyl Azetidine 
        
Only one procedure for this reaction was implemented with good results. Utilizing 
lithium aluminum hydride (LAH) for the reduction of the Boc carbonyl to a methyl group is 
standard. Work-ups when handling lithium aluminum hydride, however, can be 
problematic and therefore two different work-ups were attempted. The traditional Fieser 
work-up and a work up employing Glauber’s salt were completed. The Fieser work up was 
completed by cooling the reaction to 0°C then slowly adding X mL deionized water, X mL 
15% NaOH, three times X mL deionized water in successive order where X is the grams of 
lithium aluminum hydride used.81  
 
 
Scheme 6: Formation of N-methyl-3-aryl-3-arylmethoxyaxetidine 
 
 
Glauber’s salt (Na2SO4 • H2O) is made by recrystallization of anhydrous sodium 
sulfate in deionized water. For use of Glauber’s salt the reaction was also cooled to 0°C and 
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Glauber’s salt was slowly added until release of hydrogen is complete.82 This addition could 
take upwards of 2 hours to complete. Though the Glauber’s salt work-up takes longer to 
complete, formation of product was double in comparison to the traditional Fieser work-up, 
30% to 15% yield comparatively. 
Each N-Boc-3-aryl-3-arylmethxoyazetidine compound 35a-h, 36a-j, and 37a-n 
were reduced using LAH followed by work-up with Glauber’s salt to yield N-methyl-3-aryl-
3-arylmethxyazetidine compounds 31a-ii in 4-66% yield. 
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2.1.4 Optimization of Formation of 3-Aryl-3-arylmethoxyazetidine 
 
Removal of the Boc group was the trickiest part of the synthesis. Several methods 
were attempted before a high yielding reproducible procedure was achieved. The first 
attempt was completed by using 50% trifluoroacetic acid and 50% dichloromethane.83 
However, in this case the azetidine decomposed. This procedure was repeated multiple 
times using shorter reaction times and lower reaction temperatures.  However, the same 
results were observed, and no azetidine was isolated.  
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Scheme 7: Attempted N-Boc removal with TFA/DCM 
 
 
A milder procedure using bismuth trichloride was attempted to remove the Boc 
protecting group. N-Boc-3-phenyl-3-phenylmethoxyazetidine was dissolved in 50:1 
acetonitrile/water and BiCl3 was added.84 The reaction was heated to 55°C under nitrogen 
and stirred for 1 hour before a second dose of BiCl3 was added. The mixture was then 
stirred at 55oC overnight. After column chromatography using 25:5:70 
EtoAc:NH4OH:Hexanes the intended product was identified by 1H NMR.84 This reaction 
went to completion for small reactions, under 50 mg, with 20-25% yield. However, larger 
reactions needed longer run times, in excess of 48 hours, for the reaction to go to 
completion and the percent yield was lowered to 9%. With a minimum of 50 mg of final 
product needed for characterization and biological testing this reaction was deemed 
unfeasible due to length of run time and poor yield. 
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Scheme 8: Attempted formation of 3-Aryl-3-arylmethoxyazetidine using BiCl3 
 
 
The best method found, using 2M hydrochloric acid in ethyl acetate, is a 
modification of a synthesis by Gibson et al.85 In each deprotection the acid solution was 
freshly made (no more than 5 days old) in situ by adding 95% ethanol (1.5 equivalents) and 
acetyl chloride (1 equivalent) to dry ethyl acetate under nitrogen. The reaction was stirred 
at 0°C for 2 hours and the solution was stored in the refrigerator for up to five days. Adding 
an excess of the prepared acid solution to N-boc-3-aryl-3-arylmethoxyazetidine afforded 
the product as a hydrochloric salt in good yield within three hours. This method gave the 
best results (65% yield) while eliminating the need for more steps to make a solid as would 
have been necessary for the other attempted deprotections. 
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Scheme 9: Deprotection of N-Boc using 2M HCl/EtOAc 
 
 
Each N-Boc-3-aryl-3-arylmethxoyazetidine compound 35a-h, 36a-j, and 37a-n 
were deprotected using excess 2M HCl/EtOAc to yield 3-aryl-3-arylmethxyazetidine 
compounds 30a-ii in 8-69% yield. 
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2.1.5 Forward Synthesis and Crystallographic Representation 
 
 The overall forward synthesis for the preparation of 3-aryl-3-arylmethoxyazetidine 
is seen in Scheme 10 combining the above optimized reactions.  
 
 
Scheme 10: Synthetic route for the synthesis of 3-aryl-3-arylmethoxyazetidine and N-methyl-3-aryl-3-
arylmethoxyazetidine analogs 
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 Crystallographic data for 3-phenyl-3-phenylmethoxyazetidine (30a) was obtained 
to confirm the structure (Figure 12).  The structure was confirmed unequivocally and the 
synthetic scheme was validated.77   
 
 
 
Figure 12: X-ray structure of 3-phenyl-3-phenylmethoxyazetidine (30a) provided courtesy of Prof. Edwin 
Stevens.77 
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2.2 Binding Affinity  
 
Drugs were evaluated for their potency by the value of their binding affinity to a 
their respective transporter. This was completed by competitive inhibition against a known 
radiolabeled ligand. These ligands characteristically have high binding affinity for the 
targeted transporter. Binding studies completed for our synthesized molecules utilized 
[3H]WIN-35,428 (26) and [3H]citalopram (21) for respective dopamine and serotonin 
transporters.  
 
 
 
 
Binding values are typically expressed in terms of IC50 or Ki. IC50 is the concentration 
at which the compound is needed to displace 50% of the bound radiolabeled ligand. Ki is 
the inhibition constant and is directly related to IC50 by the Chen-Pursoff equation.86 
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[3H] is the concentration of radiolabeled ligand use and Kd is the previously determined 
dissociation constant of the radiolabeled ligand. Several factors effect the IC50 value 
including the type and amount of radiolabeled ligand used, the state of the tissue used, the 
incubation time, buffer and protein content. Due to the variety of factors Ki offers a better 
comparison of data because it takes into account [3H] and Kd. Ki is also normally reported as 
an average over multiple trials to eliminate outlying data.86 
 
 
2.3 Binding Affinities of 3-Aryl-3-arylmethoxyazetidine and N-Methyl-3-
aryl-3-arylmethoxy Analogs 
 
Each final compound was characterized either has a hydrochloric salt or in the case 
of non-salt formation the product was freebased and the oxalate salt was formed. Salts 
were evaluated for biological binding affinity at multiple monoaminergic transporters. 
The transporter binding affinities were determined for some of the 3-aryl-3-
arylmethoxyazetidine (30a-i) and N-methyl-3-aryl-3-arylmethoxyazetidine (31a-i) analogs 
and are presented in Table 2. The binding affinity values were obtained by the ability of 
the tested compounds to displace bound radiolabeled ligands from rat caudate tissue. The 
Ki values reported in Table 2 are the inhibition constants derived from the unlabeled 
ligands. The binding affinities of the novel azetidine analogs were determined at the 
dopamine and serotonin transporters by the inhibition of [3H]WIN–35,428 and 
[3H]citalopram, respectively.77  
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Table 2: Monoamine transporter affinity and selectivity77 
 
Cmpd Code X Y R 
SERT 
Ki (nM)b 
DAT 
Ki (nM)b 
DAT/SERT 
Cocaine      
32 ± 5 
388 ± 211 
 
30a ANT – 35 H H H 1230 ± 71.3 4860 ± 446 4 
31a ANT – 47 H H CH3 73.0 ± 9.4 1730 ± 318 24 
30bc ANT – 74 H 4-Cl H 2590 ± 20 3610 ± 25.1 1 
31b ANT – 73 H 4-Cl CH3 4.0 ± 0.3 3910 ± 283 705 
30cc ANT – 57 H 3,4-Cl2 H 7.3 ± 07 2820  ± 108 386 
31c ANT – 72 H 3,4-Cl2 CH3 1.0 ± 0.2 1210 ± 69.2 1210 
30d ANT – 129 4-Cl H H 825 ± 80 3180 ± 361 4 
31d ANT – 85 4-Cl H CH3 39 ± 7 1410 ± 107 36 
30e ANT – 87 4-Cl 4-Cl H 3.5 ± 0.2 3830 ± 42.4 1094 
31e ANT – 84 4-Cl 4-Cl CH3 7.8 ± 3.3 2030 ± 601 206 
30f ANT – 92 4-Cl 3,4-Cl2 H 8.1 ± 3.2 3770 ± 318 465 
31f ANT – 125 4-Cl 3,4-Cl2 CH3 3.0 ± 1.1 976 ± 61.4 325 
30g ANT – 110 3,4-Cl2 H H 209 ± 8 1300 ± 86.1 6 
31g ANT – 133 3,4-Cl2 H CH3 23.2 ± 1.6 620 ± 137 27 
30h ANT – 126 3,4-Cl2 4-Cl H 2.9 ± 0.3 3020 ± 338 1041 
31h ANT – 124 3,4-Cl2 4-Cl CH3 4.8 ± 2.2 2290 ± 513 477 
30i ANT – 108 3,4-Cl2 3,4-Cl2 H 4.2 ± 0.3 3670 ± 28.4 873 
31i ANT – 106 3,4-Cl2 3,4-Cl2 CH3 1.3 ± 0.0 436 ± 66.6 335 
aCompounds tested as hydrochloric salt unless otherwise noted. 
bAll values are mean ± SEM of three experiments performed. 
cCompound tested as oxalate salt 
  
In general compounds with N-methyl substitutions were found to have higher 
binding affinity at both dopaminergic and serotonergic systems and the corresponding 
unsubstituted analogs. The outliers with this conclusion are 31b, 31e, and 31h.  Both 30e 
and 30h show a two times higher binding affinity for serotonin for the N-H versus its N-
methyl substituted counterpart, while 31b has a slightly lower dopamine binding affinity 
than 31b.77  
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 The dichloro substituted analogs 30e and 30h were the most potent azetidines at 
SERT having binding affinities of Ki = 3.5nM and Ki = 2.9nM respectively. All compounds 
demonstrate a higher selectivity for the serotonergic system over the dopaminergic system 
exhibiting nanomolar affinity for serotonin and micromolar affinity for dopamine. 3,4-
dichloronated analog 31c demonstrated the highest serotonin selectivity (1210 
SERT/DAT) as well as binding affinity at serotonin (Ki = 1.0nM).77  
 Binding studies revealed that compounds with the 3,4-dichlorophenyl group 
attached as the 3-aryl substituent had increased dopaminergic binding affinity and a 
decreased serotonin selectivity. If the 3-arylmethoxy moiety contained a chloro substituent 
then the dopamine binding affinity decreased and the serotonin affinity dominated. 
Conversely, if the 3-arylmethoxy ligand contained the 3,4-dichloro substituent then the 
analog exhibited high serotonergic affinity. When both aryl groups contained 3,4-dichloro 
substituents little improvement of serotonin affinity or selectivity was seen.77  
 Of the 3-aryl-3-arylmethoxyazetidines tested, compound 31g proved to be most 
similar to a dual re-uptake inhibitor. N-methyl-3-(3,4-dichlorophenyl)-3-phenylazetidine 
exhibited a profile that closely approached that of a DUI with a DAT/SERT selectivity of 27 
while maintaining nanomolar affinity for both transporters. Although 31g was serotonin 
selective, the moderate dopamine affinity is promising.77 
 These trends were consistent with those seen in the 3-aryl-3-arylmethoxytropane 
series. It is clear from the preliminary binding affinity data that substitution on the aryl 
rings might lead to a potent DAT/SERT dual re-uptake inhibitor for METH addiction.77 
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 Following trends of the synthesized tropanes numerous analogs were also 
synthesized for biological trends. Table 3 lists synthesized compounds 30j-ii and 31j-ii, 
which are awaiting biological testing of dopaminergic and serotonergic binding affinities. 77 
 
Table 3: Synthesized compounds 
 
Compound Code X Y R 
30j ANT-159 H 4-F H 
31j ANT – 199 H 4-F CH3 
30k ANT-140 H 2-F H 
31k ANT – 138 H 2-F CH3 
30l ANT-141 H 3,4-F2 H 
31l ANT -139 H 3,4-F2 CH3 
30m ANT-148 4-F H H 
31m ANT -158 4-F H CH3 
30n ANT-149 4-F 4-F H 
31n ANT -147 4-F 4-F CH3 
30o ANT-160 4-F 2-F H 
31o ANT -156 4-F 2-F CH3 
30p ANT – 161 4-F 3,4-F2 H 
31p ANT -157 4-F 3,4-F2 CH3 
30q ANT – 212 3,4-F2 H H 
31q ANT - 173 3,4-F2 H CH3 
30r ANT -170 3,4-F2 4-F H 
31r ANT - 174 3,4-F2 4-F CH3 
30s ANT -171 3,4-F2 2-F H 
31s ANT - 175 3,4-F2 2-F CH3 
30t ANT -172 3,4-F2 3,4-F2 H 
31t ANT - 176 3,4-F2 3,4-F2 CH3 
30u ANT - 219 H 4-CF3 H 
31u ANT - 225 H 4-CF3 CH3 
30v ANT - 220 H 2,4-(CF3)2 H 
31v ANT - 217 H 2,4-(CF3)2 CH3 
30w ANT - 221 H 3,5-(CF3)2 H 
31w ANT - 218 H 3,5-(CF3)2 CH3 
30x ANT - 188 4-CF3 H H 
31x ANT - 184 4-CF3 H CH3 
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Table 3 continued 
30y ANT - 311 4-CF3 4-CF3 H 
31y ANT - 185 4-CF3 4-CF3 CH3 
30z ANT - 191 4-CF3 2,4-(CF3)2 H 
31z ANT - 187 4-CF3 2,4-(CF3)2 CH3 
30aa ANT - 190 4-CF3 3,5-(CF3)2 H 
31aa ANT - 186 4-CF3 3,5-(CF3)2 CH3 
30bb ANT - 262 2,4-(CF3)2 H H 
31bb ANT - 258 2,4-(CF3)2 H CH3 
30cc ANT - 263 2,4-(CF3)2 4-CF3 H 
31cc ANT - 259 2,4-(CF3)2 4-CF3 CH3 
30dd ANT - 288 2,4-(CF3)2 2,4-(CF3)2 H 
31dd ANT - 286 2,4-(CF3)2 2,4-(CF3)2 CH3 
30ee ANT - 265 2,4-(CF3)2 3,5-(CF3)2 H 
31ee ANT - 287 2,4-(CF3)2 3,5-(CF3)2 CH3 
30ff ANT - 249 3,5-(CF3)2 H H 
31ff ANT - 247 3,5-(CF3)2 H CH3 
30gg ANT - 235 3,5-(CF3)2 4-CF3 H 
31gg ANT - 238 3,5-(CF3)2 4-CF3 CH3 
30hh ANT - 250 3,5-(CF3)2 2,4-(CF3)2 H 
31hh ANT - 248 3,5-(CF3)2 2,4-(CF3)2 CH3 
30ii ANT - 236 3,5-(CF3)2 3,5-(CF3)2 H 
31ii ANT - 239 3,5-(CF3)2 3,5-(CF3)2 CH3 
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Conclusion 
 
 A novel series of N-methyl and N-H 3-aryl-3arylmethoxyazetidine analogs were 
synthesized and evaluated at dopamine and serotonin transporter ligands. The in vitro 
binding affinity for the dopamine and serotonin transporters were determined by 
competitive inhibition against radiolabeled ligands [3H]WIN-35,428 and [3H]citalopram 
respectively in rat brain tissue. The results of the binding study clearly demonstrate that 
the tested 3-aryl-3-arylmethoxyazetidine analogs were selective for the serotonin over the 
dopaminergic system. The N-methyl compounds (31) were generally found to exhibit a 
higher binding affinity and potency than their N-H companions (30).  N-methyl-3-(3,4-
dichlorophenyl)-3-phenylmethoxyazetidine (31c) had the highest potency and selectivity 
for serotonin of the tested series with a binding affinity of Ki = 1.0nM, and a serotonin 
dopamine ratio of 1210.  
 It was analog 31g, N-methyl-3-(3,4-dichlorophenyl)-3-phenylazetidine, that was 
shown to be most similar to a dual re-uptake inhibitor with a dopamine/serotonin 
selectivity of 27 and nanamolar affinity at both dopamine and serotonin receptors Ki 
=620nM and Ki =23nM respectively. Overall, this initial investigation suggested that the 
chloro-subsituted aryl rings are a key structural feature for improved serotonin and 
dopamine binding affinity.  
 Though structurally similar to its predecessor 3-aryl-3-arylmethoxytropane, the 3-
aryl-3-arylmethoxyazetidine analogs display vastly different binding affinities to both the 
dopaminergic and serotonergic systems. While both follow a similar trend, it appears the 
decreased bioavailability of the azetidine system contributes to decreased potency at both 
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serotonergic and dopaminergic transporters.  Because the 3-aryl-3-arylmethoxyazetidine 
analogs still demonstrated nanomolar affinity for both dopamine and serotonin it is still a 
viable scaffold for further testing.  
 The remaining compounds synthesized in this study are in various stages of 
biological evaluation. The potency and selectivity that will be determined for these 
compounds will provide direction for further studies with this novel 3-aryl-3-
arylmethoxyazetidine scaffold.  
  
 61
Experimental Section 
 
General Information 
Chemicals were purchased from Sigma-Aldrich Chemical Co., Oakwood Products Inc., 
and VWR International LLC and used as received or otherwise noted. Anhydrous solvents 
were purchased from EMD Millipore and were used under nitrogen without any further 
purification. Chromatography refers to column chromatography on silica gel (Silica Gel 60Å, 
230-400 mesh). Reported melting points are uncorrected. 1H NMR (400 MHz) and 13C NMR 
(100 MHz) were recorded on a Varian-400 MHz nuclear magnetic resonance spectrometer 
at ambient temperature in DMSO-d6.  1H NMR chemical shifts are reported as δ values 
(ppm) relative to tetramethylsilane.  13C NMR chemical shifts are reported as δ values 
(ppm) relative to DMSO-d6 (39.5 ppm). Elemental analyses were obtained from Atlantic 
Microlabs, Inc., Norcross, GA.    
Solvent acronyms – Tetrahydrofuran (THF), Dichloromethane (DCM), Deionized water (DI). 
 
General Procedure A: Preparation of 1-Boc-3-arylazetidin-3-ols (34b-h) 
Halogenated bromobenzene (3 equiv.) was dissolved in anhydrous THF and cooled 
to -78 °C for 10 minutes. n-butyllithium (2.5M, 3 equiv.) was added and the reaction stirred 
for 1 hour under nitrogen. 1-Boc-3-azetidinone (1 equiv.) was dissolved in anhydrous THF, 
and added via syringe to the reaction. The mixture was stirred overnight to room 
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temperature. The reaction was quenched with 10% NH4Cl, extracted with diethyl ether (3 x 
15 mL), washed with brine (15 mL), and dried over anhydrous sodium sulfate, and the 
solvent removed under reduced pressure. The crude oil was purified by column 
chromatography (30% ethyl acetate:hexanes) to afford 34b-h.  
 
General Procedure B: Preparation 3-Aryl-3-arylmethoxyazetidine 
hydrochloride 
 The azetidinols (34a-h) (1 equiv.) and tetrabutylammonium bromide (25 mg) were 
dissolved in DCM and freshly prepared 4N NaOH (5 mL DCM:6 mL NaOH per 0.1g of 
azetidinol). The corresponding benzyl bromide was added (3 equiv.) and the reaction was 
heated to 35 °C overnight. The reaction was extracted with DCM (3 x 15 mL), washed with 
brine, dried over anhydrous sodium sulfate, and the solvent removed under reduced 
pressure. The crude oil was dried on high vacuum for 1h then placed under nitrogen. 
Excess 2M HCl/EtOAc was added and the mixture was stirred at room temperature for 3-
6h. The white precipitant was filtered and triturated in diethyl ether to afford the 3-aryl-3-
arylmethoxyazetidines, 30a, 30d-z, 30bb-ii as hydrochloric salts. 
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General Procedure C: Preperation of N-methyl-3-aryl-3-
arylmethoxyazetidine 
 The azetidinols (34a-h) (1 equiv.) and tetrabutylammonium bromide (25 mg) were 
dissolved in DCM and freshly prepared 4N NaOH (5 mL DCM:6 mL NaOH per 0.1 g of 
azetidinol). The corresponding benzyl bromide was added (3 equiv.) and the reaction was 
heated to 35 °C overnight. The reaction was extracted with DCM, washed with brine, dried 
over anhydrous sodium sulfate, and the solvent removed under reduced pressure. Crude 
benzyl ether derivatives were placed on high vacuum for 1h then placed under nitrogen. 
THF (10 mL) was added and the reaction cooled to 0 °C. Lithium aluminum hydride (LAH) 
in THF (1M, 5 equiv.) was slowly added and the reaction was refluxed at 65 °C for 14h.  The 
reaction was cooled to 0 ºC, quenched with Glauber’s salt and stirred for an additional hour. 
The aluminum salts were filtered and the filtrate was concentrated under reduced pressure. 
Excess 2M HCl/EtOAc was added and the mixture stirred under nitrogen for 2h. The 
solvent was removed under reduced pressure, and the residue was triturated in diethyl 
ether to afford the pure N-methyl azetidines, 31a-j, 31m-n, 31p, 31u, 31w, 31bb-cc, and 
31ff as the hydrochloric salts.   
 
General Procedure D: Formation of Oxalic Salts 
 In the event that the hydrochloric salts were not formed in either General 
Procedures B or C, the crude 1-methyl-3-aryl-4arylmethoxyazetidine or 3-aryl-3-
arylmethoxyazetidine was dissolved in DCM (10 mL). Saturated NaHCO3 solution (10 mL), 
 64
and a minimal amount of NH4OH to achieve a pH of 11 was added. The mixture was then 
extracted with DCM (3 x 15 mL), washed with brine (15 mL) and dried over anhydrous 
sodium sulfate. The solvent was removed under reduced pressure and the remaining oil 
was dissolved in a minimal amount of diethyl ether. Oxalic acid (1.1 equiv.) was separately 
dissolved in a minimal amount of diethyl ether then slowly pipetted into the azetidine 
solution. The oxalate salts were immediately formed and collected by vacuum filtration.  
 
1-Boc-3-phenyl-3-azetidinol (34a) 
1-Boc-3-azetidinone (1 equiv) was dissolved in anhydrous THF under nitrogen, and 
cooled to -78 °C for 10 minutes. Phenyllithium (2M in THF, 3 equiv.) was slowly added and 
the mixture allowed to warm to room temperature over night. The reaction was quenched 
with 30 mL 10% NH4Cl solution. The aqueous layer was extracted with Et2O (3 x 15 mL), 
washed with brine (15 mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure and purified by column chromatography (30% EtOAc / Hexanes) to 
afford the product (34a) as a pale yellow solid (94%). MP 85.3-87.8 oC; 1H NMR (400MHz, 
CDCl3): δ 7.49(d, J = 8 Hz, 2H), 7.42-7.38(m, 2H), 7.33-7.30(m, 1H), 4.27(d, J = 9.2 Hz, 2H), 
4.16(d, J = 9.2 Hz, 2H), 1.46(s, 9H). 
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1-Boc-3-(4-chlorophenyl)-3-azetidinol (34b) 
General Procedure A. The azetidinol was obtained as a pale yellow solid (86%) mp 139.0-
140.6 oC; 1H NMR (400MHz, CDCl3): δ 7.4-7.38(m, 2H), 7.28(d, J = 8.8 Hz, 2H), 4.63(s, 1H), 
4.13-4.05(m, 4H), 1.39(s, 9H). 
 
1-Boc-3-(3,4-dichlorophenyl)-azetidinol (34c) 
General Procedure A. The azetidinol was obtained as a colorless oil (91%) 1H NMR 
(400MHz, CDCl3): δ 7.60(d, J = 2.0 Hz, 1H), 7.41(d, J = 8.4 Hz, 1H), 7.33-7.30(m, 1H), 4.56(s, 
1H), 4.12(dd, J = 9.2 Hz, J = 21.6 Hz, 4H), 1.42(s, 9H). 
 
1-Boc-3-(4-fluorophenyl)-3-azetidinol (34d) 
General Procedure A. The azetidinol was obtained as a pale yellow solid (64%); mp 90.8 - 
92.8 oC; 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.34 (m, 2H), 7.04 – 6.88 (m, 2H), 4.81 (s, 1H), 
4.08 (t, J = 5.8 Hz, 4H), 1.44 – 1.31 (m, 9H). 
 
1-Boc-3-(3,4-difluorophenyl)-3-azetidinol (34e) 
General Procedure A. The azetidinol was obtained as a yellow oil (31%); 1H NMR (400 MHz, 
CDCl3) δ 7.20 – 7.03 (m, 3H), 4.40 (d, J = 9.6 Hz, 2H), 4.15 (d, J = 9.2 Hz, 2H), 1.42 (s, 9H). 
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1-Boc-3-(4-(trifluoromethyl)phenyl)-3-azetidinol (34f) 
General Procedure A. The azetidinol was obtained as a white solid (42%); mp 147.0-147.8 
oC; 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 4.6 Hz, 4H), 4.18 (s, 4H), 1.43 (s, 9H). 
 
1-Boc-3-(2,4-bis(trifluoromethyl)phenyl)-3-azetidinol (34g) 
General Procedure A. The azetidinol was obtained as a dark orange solid (46%); mp 133.3-
135.2 oC; 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 8.2 Hz, 
1H), 4.48 (d, J = 9.7 Hz, 2H), 4.22 (d, J = 9.8 Hz, 2H), 3.19 (s, 1H), 1.44 (s, 9H). 
  
1-Boc-3-(3,5-bis(trifluoromethyl)phenyl)-3-azetidinol (34h) 
General Procedure A. The azetidinol was obtained as a dark orange solid (69%); mp 119.5-
119.9 oC; 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 2H), 7.84 (s, 1H), 4.22 (s, 4H), 3.10 (s, 1H), 
1.48 (s, 9H). 
 
3-Phenyl-3-phenylmethoxyazetidine hydrochloride (30a, ANT-35) 
General Procedure B. The azetidine was obtained as a white solid (35%); mp 153.3-155.2 
oC; 1H NMR (400MHz, DMSO-d6): δ 7.49-748(m, 4H), 7.27-7.31(m, 6H), 4.37(d, J = 11.6 Hz, 
2H), 4.26 (d, J = 11.6 Hz, 2H), 4.12(s, 2H); 13C NMR (100 MHz, DMSO-d6): δ 138.4, 138.0, 
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129.4, 128.9, 128.3, 127.1, 79.0, 66.1, 55.7. Anal. Calcd. for C16H17NO•HCl: C, 69.68; H, 6.58; 
N, 5.08. Found: C, 69.42; H, 6.59; N, 5.15. 
      
3-Phenyl-3-(4-chlorophenyl)methoxyazetidine oxalate (30b, ANT-74) 
General Procedures B and D. The azetidine was obtained as a white solid (22%); mp 207.3-
208.9 oC; 1H NMR (400 MHz, DMSO-d6): δ 7.48-7.30(m, 9H), 4.42-4.31(m, 4H), 4.10(s, 2H); 
13C NMR (100 MHz, DMSO-d6): δ 162.9, 138.3, 137.1, 134.6, 132.7, 131.1, 130.1, 129.4, 
129.3, 128.8, 127.2, 77.2, 65.3, 62.7, 57.9. Anal. Calcd. for C16H16ClNO•C2H2O4: C, 59.43; H, 
4.99; N, 3.85. Found: C, 59.11; H, 5.17; N, 3.62. 
 
3-Phenyl-3-(3,4-dichlorophenyl)methoxyazetidine oxalate (30c, ANT- 57) 
General Procedures B and D. The azetidine was obtained as a white solid (29%); mp 179.3-
181.4 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.62-7.92(m, 8H), 4.43(d, J = 11.2 Hz, 2H), 4.31(d, 
J = 11.2 Hz, 2H), 4.16(s, 2H); 13C NMR (100 MHz, DMSO-d6): δ 163.3, 139.6, 139.2, 131.0, 
130.6, 129.8, 129.4, 129.3, 129.1, 128.3, 127.1, 77.3, 64.6, 63.3, 58.6. Anal. Calcd. for 
C16H15Cl2NO•C2H2O4• H2O: C, 41.83; H, 4.39; N, 2.44. Found: C, 41.77; H, 4.30; N, 2.21. 
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3-(4-Chlorophenyl)-3-phenylmethoxyazetidine hydrochloride (30d, ANT-129) 
General Procedures B. The azetidine was obtained as a white solid (41%); mp 210.3-211.2 
oC; 1H NMR (400 MHz, DMSO-d6): δ 7.56-7.51(m, 4H), 7.31-7.23(m, 5H), 4.34(d, J = 12.0 Hz, 
2H), 4.22(d, J = 12.0 Hz, 2H), 4.14(s, 2H); 13C NMR (100 MHz, DMSO-d6): δ 137.9, 137.5, 
134.1, 19.4, 129.2, 128.8, 128.3, 128.3, 78.4, 66.1, 55.4. Anal. Calcd. for C16H16ClNO•HCl: C, 
61.95; H, 5.52; N, 4.52. Found: C, 61.28; H, 5.76; N, 4.46. 
 
3-(4-Chlorophenyl)-3-(4-chlorophenyl)methoxyazetidine hydrochloride (30e, ANT-87) 
General Procedure B. The azetidine was obtained as a white solid (44%); mp 171.5-173.4 
oC; 1H NMR (400 MHz, DMSO-d6): δ 7.53(t, J = 10.4 Hz, 4H), 7.39-7.33(m, 4H), 4.35(d, J = 
11.6 Hz, 2H), 4.25(d, J = 11.2 Hz, 2H), 4.14(s, 2H); 13C NMR(100 MHz, DMSO-d6): δ 155.3, 
137.4, 137.0, 134.2, 132.8, 130.1, 129.4, 129.2, 128.8, 78.6, 65.3, 55.6. Anal. Calcd. for 
C16H15Cl2NO•HCl: C, 55.76; H, 4.68; N, 4.06. Found: C, 55.4; H, 4.87; N, 3.91. 
 
3-(4-Chlorophenyl)-3-(3,4-dichlorophenyl)methoxyazetidine hydrochloride (30f, ANT-
92)  
General Procedure B. The azetidine was obtained as a white solid (65%); mp 197.7-199.4 
oC; 1H NMR (400 MHz, DMSO-d6): δ 7.63(s, 1H), 7.58-7.49(m, 5H), 7.31(d, J = 8.4 Hz 1H), 
4.35(d, J  = 11.6 Hz, 2H), 4.26 (d, J = 11.6 Hz, 2H), 4.16(s, 2H); 13C NMR (100 MHz, DMSO-
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d6): δ 139.3, 137.2, 134.3, 131.6, 131.0, 130.7, 130.1, 129.4, 129.2, 128.4, 78.8, 64.7, 55.5.  
Anal. Calcd. for C16H14Cl3NO•HCl: C, 50.69; H, 3.99; N, 3.69. Found: C, 50.11; H, 3.97; N, 3.54. 
 
3-(3,4-Dichlorophenyl)-3-phenylmethoxyazetidine hydrochloride (30g, ANT-110) 
General Procedure B. The azetidine was obtained as a white solid (46%); mp 184.6-186.1 
oC; 1H NMR (400 MHz, DMSO-d6): δ 7.79(s, 1H), 7.28(s, 5H), 7.70(s, 1H), 7.48(s, 1H), 4.50-
4.11(m, 6H); 13C NMR (100 MHz, DMSO-d6): δ 139.6, 137.7, 132.2, 131.6, 129.6, 128.9, 
128.4, 127.7, 78.1, 66.4, 55.4.  Anal. Calcd. for C16H15Cl2NO•HCl•H2O: C, 52.99; H, 5.00; N, 
3.86. Found: C, 52.89 H, 5.23; N, 3.82. 
 
3-(3,4-Dichlorophenyl)-3-(4-chlorophenyl)methoxyazetidine hydrochloride (30h, ANT-
126)  
General Procedure B. The azetidine was obtained as a white solid (28%); mp 148.2-149.8 
oC; 1H NMR (400 MHz, DMSO-d6): δ 7.81(s, 1H), 7.72(d, J = 8.4 Hz, 1H), 7.48 (dd, J = 6.0 Hz, J 
= 2.4 Hz, 1H), 7.33(s, 4H), 4.38(d, J = 12.0 Hz, 2H), 4.25(d, J = 12.0 Hz, 2H), 4.18(s, 2H); 13C 
NMR (100 MHz, DMSO-d6): δ 139.4, 136.9, 132.9, 132.2, 131.6, 130.1, 129.6, 128.8, 127.6, 
78.3, 65.5, 55.9, 55.4.  Anal. Calcd. for C16H14Cl3NO•HCl•H2O: C, 48.39; H, 4.31; N, 3.51. 
Found: C, 48.17 H, 4.26; N, 3.51. 
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3-(3,4-Dichlorophenyl)-3-(3,4-dichlorophenyl)methoxyazetidine hydrochloride (30i, 
ANT-108). 
General Procedure B. The azetidine was obtained as a white solid (62%); mp 196.7-197.6 
oC; 1H NMR (400 MHz, DMSO-d6): δ 7.79(s, 1H), 7.71(d, J = 8.4 Hz, 1H), 7.61 (s, 1H), 7.55(d, J 
= 8.4 Hz, 1H), 7.47(d, J = 8.0 Hz, 1H), 7.31(d, J = 8.4 Hz, 1H), 4.38 (d, J =12.0 Hz, 2H), 4.26 (d, 
J = 11.6 Hz, 2H), 4.20(s, 2H); 13C NMR (100 MHz, DMSO-d6): δ 139.2, 139.1, 131.6, 131.5, 
130.9, 130.7, 130.1, 129.6, 128.5, 127.6, 78.4, 64.9, 55.3.  Anal. Calcd. for C16H13Cl4NO•HCl: 
C, 46.47; H, 3.41; N, 3.39. Found: C, 46.18 H, 3.58; N, 3.34. 
 
3-Phenyl-3-(4-fluorophenyl)methoxyazetidine hydrochloride (30j, ANT-159)  
General Procedure B. The azetidine was obtained as a pale yellow solid (25%); mp 157.8-
159.3 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.54 – 7.32 (m, 7H), 7.14 (t, J = 8.9 Hz, 2H), 4.35 (d, 
J = 11.8 Hz, 2H), 4.25 (d, J = 11.8 Hz, 2H), 4.12 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 163.5, 
161.1, 138.5, 134.3, 130.5, 130.4, 129.5, 127.1, 115.8, 115.6, 79.0, 75.8, 65.4, 55.5. Anal. 
Calcd. for C16H16NOF•HCl: C, 65.42; H, 5.83; N, 4.77. Found: C, 65.22; H, 5.94; N, 4.66. 
 
3-Phenyl-3-(2-fluorophenyl)methoxyazetidine hydrochloride (30k, ANT-140)  
General Procedure B. The azetidine was obtained as a white solid (24%); mp 160.0-162.1 
oC; 1H NMR (400 MHz, D2O) δ 7.39 – 7.26 (m, 5H), 7.20 (dd, J = 15.3 Hz, J = 7.5, 1H), 7.08 (dd, 
J = 8.2 Hz, J = 6.7 Hz, 1H), 7.04 – 6.87 (m, 2H), 4.45 (d, J = 12.3 Hz, 2H), 4.25 (d, J = 12.3 Hz, 
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2H), 4.02 (s, 2H). 13C NMR (100 MHz, D2O) δ 162.2, 159.8, 136.3, 123.2, 115.6, 115.4, 79.2, 
60.8, 60.7, 55.8, 23.3, 19.3, 13.00. Anal. Calcd. for C16H16NOF•HCl: C, 65.42; H, 5.83; N, 4.77. 
Found: C, 65.39; H, 5.8; N, 4.72. 
 
3-Phenyl-3-(3,4-difluorophenyl)methoxyazetidine hydrochloride (30l, ANT-141)  
General Procedure B. The azetidine was obtained as a white solid (24%); mp 105.4-108.3 
oC; 1H NMR (400 MHz, DMSO-d6) δ 7.46 (t, J = 8.2 Hz, 5H), 7.42 (d, J = 5.2 Hz, 1H), 7.39 – 
7.31 (m, 1H), 7.13 (d, J = 7.9 Hz, 1H), 4.38 (d, J = 12.0 Hz, 2H), 4.27 (d, J = 12.0 Hz, 2H), 4.12 
(s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 191.2, 155.3, 138.2, 129.6, 129.5, 127.1, 125.0, 
118.0, 117.8, 117.4, 117.3, 79.3, 64.9. Anal. Calcd. for C16H15F2NO•HCl: C, 61.49; H, 5.17; N, 
4.49. Found: C, 61.29; H, 5.5; N, 4.22. 
 
3-(4-Fluorophenyl)-3-phenylmethoxyazetidine hydrochloride (30m, ANT-148)  
General Procedure B. The azetidine was obtained as a white solid (32%); mp 184.7-186.4 
oC; 1H NMR (400 MHz, DMSO-d6) δ 7.62 – 7.54 (m, 2H), 7.35 – 7.23 (m, 7H), 4.34 (d, J = 11.6 
Hz, 2H), 4.25 (d, J = 11.5 Hz, 2H), 4.14 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 164.0, 161.6, 
138.0, 135.0, 129.6, 129.6, 128.9, 128.4, 128.3, 116.4, 116.2, 78.5, 75.8, 66.1, 55.5. Anal. 
Calcd. for C16H16FNO•HCl: C, 65.44; H, 5.83; N, 4.77. Found: C, 65.72; H, 6.04; N, 4.56. 
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3-(4-Fluorophenyl)-3-(2-fluorophenyl)methoxyazetidine hydrochloride (30o, ANT-160)  
General Procedure B. The azetidine was obtained as a white solid (25%); mp 154.3-156.2 
oC; 1H NMR (400 MHz, DMSO-d6) δ 7.57 (dd, J = 7.3 Hz, J = 5.5 Hz, 2H), 7.49 (t, J = 7.2 Hz, 1H), 
7.32 (dd, J = 17.5 Hz, J = 8.7 Hz, 3H), 7.22 – 7.09 (m, 2H), 4.34 (d, J = 11.2 Hz, 2H), 4.25 (d, J = 
11.0 Hz, 2H), 4.18 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 164.0, 161.9, 161.6, 159.5, 134.7, 
131.2, 130.7, 129.7, 129.6, 124.8, 116.4, 116.1, 115.9, 115.7, 78.6, 60.1, 55.5 Anal. Calcd. for 
C16H15F2NO•HCl: C, 61.64; H, 5.17; N, 4.49. Found: C, 61.55; H, 5.23; N, 4.33. 
 
3-(4-Fluorophenyl)-3-(4-fluorophenyl)methoxyazetidine hydrochloride (30n, ANT-149)  
General Procedure B. The azetidine was obtained as a white solid (46%); mp 174.5-176.1 
oC; 1H NMR (400 MHz, DMSO-d6) δ 7.61 – 7.52 (m, 2H), 7.34 – 7.114  (m, 2H), 7.13 (dd, J = 
12.3 Hz, J = 5.4 Hz, 2H), 4.34 (d, J = 11.3 Hz, 2H), 4.25 (d, J = 11.3 Hz, 2H), 4.12 (s, 2H). 13C 
NMR (100 MHz, DMSO-d6) δ 164.0, 163.5, 161.6, 161.1, 134.9, 134.3, 134.3, 130.5, 129.5, 
116.2, 115.6, 78.6, 65.4, 55.5. Anal. Calcd. for C16H15F2NO•HCl: C, 61.64; H, 5.17; N, 4.49. 
Found: C, 61.42; H, 5.24; N, 4.36. 
 
3-(4-Fluorophenyl)-3-(3,4-difluorophenyl)methoxyazetidine hydrochloride (30p, ANT-
161)  
General Procedure B. The azetidine was obtained as a lime green solid (31%); mp 182.2-
184.3 oC; 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 2H), 7.60 – 7.42 (m, 3H), 7.33 – 7.28 (m, 
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3H), 7.17 (s, 1H), 4.35 (d, J = 11.4 Hz, 2H), 4.26 (d, J = 11.4 Hz, 2H), 4.14 (s, 2H). 13C NMR 
(100 MHz, DMSO-d6) δ 164.1, 161.6, 136.0, 134.7, 129.6, 129.6, 125.0, 118.0, 117.8, 117.5, 
117.3, 116.4, 116.2, 78.8, 64.9, 55.5. Anal. Calcd. for C16H14F3NO•HCl: C, 58.28; H, 4.59; N, 
4.25. Found: C, 58.22; H, 4.64; N, 4.66. 
 
3-(3,4-Difluorophenyl)-3-phenylmethoxyazetidine hydrochloride (30q, ANT-212)  
General Procedure B. The azetidine was obtained as a white solid (44%); mp 185.2-186.0 
oC; 1H NMR (400 MHz, DMSO-d6) δ 9.89 (s, 1H), 9.71 (s, 1H) 7.69 (dd, J = 13.6 Hz, J = 5.6 Hz, 
1H), 7.56 (dt, J = 19.2 Hz, 5.5 Hz, 1H), 7.40 (d, J = 7.6, 1H), 7.33-7.27 (m, 5H), 4.36 (d, J = 
11.2, 2H), 4.25 (d, J = 12.2 Hz, 2H), 4.19 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 155.3, 
151.3, 148.9, 137.9, 136.6, 128.9, 128.4, 124.5, 118.5, 117.0, 78.2, 66.3, 55.4. Anal. Calcd. for 
C16H15F2NO•HCl: C, 61.64; H, 5.17; N, 4.49. Found: C, 61.39; H, 5.32; N, 4.37. 
 
3-(3,4-Difluorophenyl)-3-(4-fluorophenyl)methoxyazetidine hydrochloride (30r, ANT-
170)  
General Procedure B. The azetidine was obtained as a white solid (26%); mp 202.8-204.0 
oC; 1H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 2H), 7.53 (dd, J = 7.5 Hz, J = 2.7 Hz, 1H), 7.42 – 
7.30 (m, 4H), 7.13 (dd, J = 12.3 Hz, J = 5.4 Hz, 2H), 4.48 (d, J = 12.0 Hz, 2H), 4.31 (d, J = 12.3 
Hz, 2H), 4.21 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 161.1, 134.1, 130.6, 130.5, 125.7, 
125.1, 119.4, 119.3, 115.3, 115.5, 76.9, 65.7, 55.4. Anal. Calcd. for C16H17F3NO•HCl•½ H2O: C, 
56.72; H, 4.46; N, 4.13. Found: C, 56.89; H, 4.57; N, 4.00. 
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3-(3,4-Difluorophenyl)-3-(2-fluorophenyl)methoxyazetidine hydrochloride (30s, ANT-
171)  
General Procedure B. The azetidine was obtained as a white solid (4%); mp 185.9-187.7 oC; 
1H NMR (400 MHz, DMSO-d6) δ 9.83 (s, 2H), 7.53 (dd, J = 17.4 Hz, J = 8.5 Hz, 1H), 7.47 – 7.37 
(m, 2H), 7.37 – 7.28 (m, 2H), 7.13 (dt, J = 14.7 Hz, 8.0 Hz, 2H), 4.48 (d, J = 12.1 Hz, 2H), 4.31 
(d, J = 12.3 Hz, 2H), 4.27 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 161.9, 159.5, 131.3, 130.8, 
127.4, 125.6, 125.2, 125.0, 124.7, 124.6, 119.5, 119.3, 115.9, 115.7, 76.9, 60.4, 55.20. Anal. 
Calcd. for C16H14F3NO•HCl: C, 58.28; H, 4.59; N, 4.25. Found: C, 57.91; H, 4.77; N, 4.13. 
 
3-(3,4-Difluorophenyl)-3-(3,4-difluorophenyl)methoxyazetidine hydrochloride (30t, 
ANT-172)  
General Procedure B. The azetidine was obtained as a yellow/green solid (26%); mp 164.7-
166.9 oC; 1H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 2H), 7.52– 7.42 (m, 2H), 7.32 (s, 3H), 7.14 
(s, 1H), 4.47 (d, J = 9.7 Hz, 2H), 4.31 (d, J = 10.2 Hz, 2H), 4.22 (s, 2H). 13C NMR (100 MHz, 
DMSO-d6) δ 151.7, 149.3, 135.7, 127.4, 127.3, 125.1, 119.5, 119.3, 117.9, 117.7, 117.5, 117.4, 
77.0, 65.2, 58.2, 55.2. Anal. Calcd. for C16H13F4NO•HCl: C, 55.26; H, 4.06; N, 4.03. Found: C, 
54.93; H, 4.18; N, 3.88. 
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3-Phenyl-3-(4-(trifluoromethyl)phenyl)methoxyazetidine hydrochloride (30u, ANT-
219) 
General Procedure B. The azetidine was obtained as a white solid (20%); mp 166.8-169.4 
oC; 1H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 2H), 7.67 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.1 Hz, 
2H), 7.53 – 7.39 (m, 5H), 4.37 (d, J = 11.8 Hz, 2H), 4.28 (d, J = 11.8 Hz, 4H). 13C NMR (100 
MHz, DMSO-d6) δ 143.0, 138.4, 129.5, 129.5, 128.7, 127.1, 125.7, 125.7, 95.7, 79.2, 75.8, 
65.3, 55.5, 16.1. Anal. Calcd. for C17H16F3NO•HCl: C, 59.39; H, 4.89; N, 4.07. Found: C, 59.14; 
H, 5.22; N, 3.89. 
 
3-Phenyl-3-(2,4-bis(trifluoromethyl)phenyl)methoxyazetidine hydrochloride (30v, 
ANT-220) 
General Procedure B. The azetidine was obtained as a white solid (41%); mp 170.2-137.1 
oC; 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 2H), 8.19 (d, J = 8.2 Hz, 1H), 8.07 (d, J = 8.2 Hz, 
1H), 7.91 (s, 1H), 7.48 – 7.40 (m, 5H), 4.46 – 4.29 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ 
141.3, 137.8, 131.9, 130.2, 129.7, 129.4, 129.2, 127.7, 127.4, 127.1, 125.3, 123.1, 122.5, 79.5, 
75.8, 61.8, 55.3. Anal. Calcd. for C18H15F6NO•HCl: C, 52.5; H, 3.92; N, 3.4. Found: C, 52.37; H, 
3.9; N, 3.21. 
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3-Phenyl-3-(3,5-bis(trifluoromethyl)phenyl)methoxyazetidine hydrochloride (30w, 
ANT-221) 
General Procedure B. The azetidine was obtained as a white solid (28%); mp 136.4-139.2 
oC; 1H NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H), 9.66 (s, 1H), 8.02 – 7.96 (m, 3H), 7.56 – 7.30 
(m, 5H), 4.50 – 4.26 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ 155.3, 141.8, 138.1, 130.9, 
130.6, 130.2, 129.6, 129.4, 128.8, 127.2, 125.3, 122.6, 121.8, 79.5, 75.8, 64.7, 55.4. Anal. 
Calcd. for C18H15F6NO•HCl: C, 52.5; H, 3.9; N, 3.4. Found: C, 52.17; H, 4.07; N, 3.12. 
 
3-(4-(Trifluoromethyl)phenyl-3-phenylmethoxyazetidine hydrochloride (30x, ANT-
188) 
General Procedure B. The azetidine was obtained as a white solid (30%); mp 209.7-210.8 
oC; 1H NMR (400 MHz, DMSO-d6) δ 10.14 (s, 2H), 7.84 – 7.79 (m, 4H), 7.29 (dt, J = 12.2 Hz, 
7.0 Hz, 5H), 4.38 – 4.28 (m, 4H), 4.18 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 143.3, 137.9, 
130.0, 129.6, 128.9, 128.4, 128.3, 128.2, 126.3, 126.3, 126.1, 123.4, 78.5, 75.8, 66.3, 55.1. 
Anal. Calcd. for C17H16F3NO•HCl: C, 59.39; H, 4.98; N, 4.07. Found: C, 59.12; H, 5; N, 3.88. 
 
3-(4-(Trifluoromethyl)phenyl-3-(4-(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30y, ANT-311) 
General Procedure B. The azetidine was obtained as a white solid (21%); mp 106.7-107.8 
oC; 1H NMR (400 MHz, DMSO-d6) δ 10.15 – 10.12 (m, 1H), 9.85 (s, 1H), 7.92 – 7.71 (m, 4H), 
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7.65 – 7.57 (m, 4H), 4.60 – 4.24 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ 193.3, 166.8, 
147.7, 143.0, 131.3, 130.7, 130.1, 129.8, 129.0, 128.7, 128.2, 127.00, 126.3, 125.6, 78.8, 72.7, 
65.6, 59.7, 55.2.  
 
3-(4-(Trifluoromethyl)phenyl-3-(2,4-bis(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30z, ANT-191) 
General Procedure B. The azetidine was obtained as a white solid (33%); mp 214.5-215.7 
oC; 1H NMR (400 MHz, DMSO-d6) δ 9.66 (s, 2H), 8.03 (s, 2H), 7.97 (s, 1H), 7.81 (d, J = 8.4 Hz, 
2H), 7.73 (d, J = 8.0 Hz, 2H), 4.48 – 4.34 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ 142.6, 
141.6, 130.9, 130.5, 130.2, 129.8, 129.5, 129.0, 128.3, 126.3, 125.3, 122.6, 121.9, 79.1, 64.9, 
55.3. Anal. Calcd. for C19H14F6NO•HCl•1H2O: C, 45.75; H, 3.29; N, 2.54. Found: C, 45.79; H, 
3.52; N, 2.76. 
 
3-(4-(Trifluoromethyl)phenyl-3-(3,5-bis(trifluoromethyl)phenyl)methoxyazetidine 
oxalate (30aa, ANT-190) 
General Procedures B and D. The azetidine was obtained as a white solid (33%); mp 164.6-
166.3 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.15 – 7.99 (m, 2H), 7.93 (s, 2H), 7.88 – 7.69 (m, 
3H), 4.55 – 4.32 (m, 2H), 4.01 (s, 1H), 3.81 (d, J = 8.0 Hz, 1H), 3.63 (d, J = 8.0 Hz, 1H). 13C 
NMR (100 MHz, DMSO-d6) δ 162.7, 145.8, 142.2, 141.7, 140.9, 130.2, 129.7, 129.3, 128.3, 
127.6, 126.2, 125.3, 123.3, 122.6, 79.3, 77.4, 64.6, 62.2, 58.5, 55.5. Anal. Calcd. for 
C19H14F9NO•C2H2O4•1H2O: C, 45.75; H, 3.29; N, 2.54. Found: C, 45.7; H, 3.31; N, 2.49. 
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3-(2,4-Bis(trifluoromethyl)phenyl-3-phenylmethoxyazetidine hydrochloride (30bb, 
ANT-262) 
General Procedure B. The azetidine was obtained as a pale yellow solid (29%); mp 187.2-
188.5 oC; 1H NMR (400 MHz, DMSO-d6) δ 9.93 (s, 2H), 8.18 (s, 1H), 8.09-8.03 (m, 1H), 7.27 
(s, 5H), 4.56 - 4.30 (m, 4H), 4.08 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 139.8, 137.5, 132.5, 
131.2, 130.9, 130.2, 128.8, 128.5, 128.4, 125.7, 125.1, 122.4, 79.2, 66.6, 55.0.  
 
3-(2,4-Bis(trifluoromethyl)phenyl-3-(4-(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30cc, ANT-263) 
General Procedure B. The azetidine was obtained as a white solid (38%); mp 183.6-185.3 
oC; 1H NMR (400 MHz, DMSO-d6) δ 10.19 – 9.88 (m, 2H), 8.16 – 8.04 (m, 3H), 7.58 – 7.52 (m, 
4H), 4.82 – 3.96 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ 142.4, 139.6, 132.6, 131.3, 130.9, 
130.3, 128.9, 126.2, 125.6, 125.1, 123.5, 122.3, 79.3, 65.8, 55.0.  
 
3-(2,4-Bis(trifluoromethyl)phenyl-3-(2,4-bis(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30dd, ANT-288) 
General Procedure B. The product was obtained as a white solid (26%); mp 191.8-192.7 oC; 
1H NMR (400 MHz, DMSO-d6) δ 9.99 (s, 2H), 8.23 (d, J = 7.9 Hz, 2H), 8.07 (d, J = 8.8 Hz, 3H), 
7.86 (s, 1H), 4.65 (d, J = 12.2 Hz, 2H), 4.37 (d, J = 17.1 Hz, 4H). 13C NMR (100 MHz, DMSO-
d6) δ 140.6, 139.0, 132.6, 132.0, 131.5, 131.1, 130.1, 129.6, 129.3, 128.8, 128.5, 127.7, 127.3, 
125.5, 122.9, 79.7, 62.0, 54.8.  
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3-(2,4-Bis(trifluoromethyl)phenyl-3-(3,5-bis(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30ee, ANT-265) 
General Procedure B. The product was obtained as a white solid (8%); mp 207.2-208.5 oC; 
1H NMR (400 MHz, DMSO-d6) δ 9.82 (s, 2H), 8.20 (d, J = 8.1 Hz, 1H), 8.09 (s, 1H), 7.99 (t, J = 
10.4 Hz, 4H), 4.63 (d, J = 12.2 Hz, 2H), 4.38 (d, J = 13.5 Hz, 4H). 13C NMR (100 MHz, DMSO-
d6) δ 141.2, 139.4, 132.5, 131.3, 130.8, 130.5, 130.3, 130.0, 128.7, 128.4, 125.6, 125.3, 125.0, 
122.6, 122.4, 121.9, 79.6, 65.0, 55.0.  
 
3-(3,5-Bis(trifluoromethyl)phenyl-3-phenylmethoxyazetidine hydrochloride (30ff, 
ANT-249) 
General Procedure B. The product was obtained as a green solid (47%); mp 141.8-144.1 oC; 
1H NMR (400 MHz, DMSO-d6) δ 10.12 – 9.66 (m, 2H), 8.22- 8.13 (m, 2H), 8.01 – 7.94 (m, 2H), 
7.43 – 7.36 (m, 2H), 7.17 (s, 2H), 4.69 – 4.01 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ 167.8, 
164.9, 146.4, 134.9, 133.4, 131.3, 130.3, 130.0, 130.0, 128.7, 128.2, 128.0, 127.2, 123.1, 78.2, 
67.0, 59.5, 55.5. Anal. Calcd. for C18H15F6NO•HCl: C, 52.5; H, 3.92; N, 3.4. Found: C, 52.33; H, 
4.11; N, 3.17. 
 
 
 
 80
3-(3,5-Bis(trifluoromethyl)phenyl-3-(4-(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30gg, ANT-235) 
General Procedure B. The product was obtained as a white solid (64%); mp 176.6-178.3 oC; 
1H NMR (400 MHz, DMSO-d6) δ 9.90 (s, 2H), 8.20 – 8.09 (m, 3H), 7.61 – 7.50 (m, 4H), 4.66 – 
4.16 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ 142.7, 141.9, 131.5, 131.1, 128.7, 128.6, 126.1, 
125.6, 125.2, 123.3, 122.5, 78.6, 75.8, 65.9, 55.2.  
 
3-(3,5-Bis(trifluoromethyl)phenyl-3-(2,4-bis(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30hh, ANT-250) 
General Procedure B. The product was obtained as a white solid (46%); mp 155.8-157.2 oC; 
1H NMR (400 MHz, DMSO-d6) δ 9.89 (s, 2H), 8.26 – 7.95 (m, 5H), 7.84 (s, 1H), 4.60 – 4.26 (m, 
6H). 13C NMR (100 MHz, DMSO-d6) δ 141.0, 140.7, 132.5, 131.7, 130.7, 129.7, 129.4, 128.7, 
127.9, 127.6, 125.1, 123.3, 123.0, 122.3, 78.9, 62.4, 55.0.  
 
3-(3,5-Bis(trifluoromethyl)phenyl-3-(3,5-bis(trifluoromethyl)phenyl)methoxyazetidine 
hydrochloride (30ii, ANT-236) 
General Procedure B. The product was obtained as a white solid (40%); mp 183.1-183.4 oC; 
1H NMR (400 MHz, DMSO-d6) δ 10.10 - 9.71 (m, 2H), 8.16 (s, 2H), 8.02 (s, 1H), 7.87 (s, 3H), 
4.61 – 4.46 (m, 4H), 4.38 (d, J = 11.2 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 141.7, 141.67, 
131.4, 131.1, 130.9, 130.5, 128.7, 125.2, 125.1, 123.3, 122.5, 122.4, 121.7, 78.9, 75.8, 65.3, 
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55.1. Anal. Calcd. for C20H13F12NO•HCl: C, 43.58; H, 2.58; N, 52.56. Found: C, 43.5; H, 2.4; N, 
2.22. 
 
N-Methyl-3-phenyl-3-phenylmethoxyazetidine hydrochloride (31a, ANT-47)  
General Procedure C. The product was obtained as a white solid. (38%); mp 164.8-166.6 oC; 
1H NMR (400 MHz, DMSO-d6): δ 7.51-7.42(m, 5H), 7.31-7.24(m, 5H), 4.45(s, 4H), 4.12(s, 
2H), 2.89(s, 3H); 13C NMR (100 MHz, DMSO-d6): δ137.8, 129.5, 129.4, 128.8, 128.4, 128.3, 
127.2, 66.2, 64.3. Anal. Calcd. for C17H19NO•HCl: C, 70.44; H, 6.97; N, 4.83. Found: C, 69.09; 
H, 7.02; N, 4.80. 
 
N-Methyl-3-phenyl-3-(4-chlorophenyl)methoxyazetidine hydrochloride (31b, ANT-73) 
General Procedure C. The product was obtained as a pale yellow solid (18%); mp 165.3-
168.9 oC; 1H NMR (400 MHz, DMSO-d6): δ 7.47-7.32(m, 9H), 4.65-4.39(m, 4H), 4.14(s, 2H), 
2.85(s, 3H); 13C NMR (100 MHz, DMSO-d6): δ137.0, 132.8, 130.3, 129.6, 129.4, 128.8, 128.4, 
127.2, 65.4, 64.2. Anal. Calcd. for C17H18ClNO•HCl: C, 62.97; H, 5.91; N, 4.32. Found: C, 
62.88; H, 5.72; N, 4.09. 
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N-Methyl-3-phenyl-3-(3,4-dichlophenyl)methoxyazetidine hydrochloride (31c, ANT-72) 
General Procedure C. The product was obtained as a white solid (19%); mp 191.8-194.1 oC; 
1H NMR (400 MHz, DMSO-d6): δ 7.58-7.29 (m, 8H), 4.47(s, 4H), 4.15(s, 2H); 2.89(s, 3H); 13C 
NMR (100 MHz, DMSO-d6): δ 131.0, 130.7, 130.2, 130.2, 129.7, 129.5, 128.5, 128.8, 128.5, 
127.2, 64.8, 64.5. Anal. Calcd. for C17H17Cl2NO•HCl: C, 56.92; H, 5.06; N, 3.90. Found: C, 
56.00; H, 5.50; N, 3.60.   
 
N-Methyl-3-(4-Chlorophenyl-3-phenylmethoxyazetidine hydrochloride (31d, ANT-85) 
General Procedure C. The product was obtained as a pale yellow solid (44%); mp 176.6-
178.6 oC; 1H NMR (400 MHz, DMSO-d6): δ 7.56-7.47(m, 4H), 7.32-7.28(m, 5H), 4.43(s, 4H), 
4.14(s, 2H), 2.88(s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 137.8, 137.0, 134.2, 129.5, 129.4, 
128.8, 128.5, 128.3, 127.2, 66.3, 64.8. Anal. Calcd. for C17H18ClNO•HCl: C, 62.97; H, 5.91; N, 
4.32. Found: C, 62.84; H, 6.02; N, 4.29. 
 
N-Methyl-3-(4-chlorophenyl)-3-(4-chlorophenyl)methoxyazetidine hydrochloride (31e, 
ANT-84)  
General Procedure C. The product was obtained as a pale green solid (24%); mp 185.7-
189.4 oC; 1H NMR (400 MHz, DMSO-d6): δ 7.56-7.50(m, 4H), 7.37-7.30(m, 4H), 4.43(s, 4H), 
4.14(s, 2H), 2.88(s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 136.9, 134.3, 132.9, 130.2, 129.4, 
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128.8, 95.6, 65.5, 64.4. Anal. Calcd. for C17H17Cl2NO•HCl: C, 54.20; H, 5.35; N, 3.72. Found: C, 
54.36; H, 5.16; N, 3.88. 
 
N-Methyl-3-(4-chlorophenyl)-3-(3,4-dichlorophenyl)methoxyazetidine hydrochloride 
(31f, ANT-125) 
General Procedure C. The product was obtained as a white solid (33%); mp 169.1-170.2 oC; 
1H NMR (400 MHz, DMSO-d6): δ 7.68-7.30 (m, 7H), 4.63-4.36 (m, 4H), 4.15 (s, 2H), 2.84(s, 
3H); 13C NMR (100 MHz, DMSO-d6): 139.0, 136.7, 134.3, 131.5, 130.9, 130.7, 130.2, 139.4, 
128.6, 128.2, 64.9, 64.0. Anal. Calcd. for C17H16Cl3NO•HCl: C, 51.94; H, 4.36; N, 3.56. Found: 
C, 51.47 H, 4.77; N, 3.49. 
 
N-Methyl-3-(3,4-dichlorophenyl)-3-phenylmethoxyazetidine hydrochloride (31g, ANT-
133) 
General Procedure C. The product was obtained as a white solid (28%); mp 180.9-182.3 oC; 
1H NMR (400 MHz, DMSO-d6): δ 7.58-7.49(m, 3H), 7.32-7.26 (m, 5H), 4.45(s, 4H), 4.17-
4.13(m, 2H), 2.88(s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 137.7, 134.2, 131.4, 129.5, 129.4, 
128.8, 128.5, 128.3, 127.3, 75.7, 66.4, 64.1. Anal. Calcd. for C17H17Cl2NO•HCl: C, 56.92; H, 
5.06; N, 3.90. Found: C, 56.83 H, 5.19; N, 3.77. 
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N-Methyl-3-(3,4-dichlorophenyl)-3-(4-chlorophenyl)methoxyazetidine hydrochloride 
(31h, ANT-124)  
General Procedure C. The product was obtained as a white solid (23%); mp 160.7-162.8 oC; 
1H NMR (400 MHz, DMSO-d6): δ 7.51-7.35(m, 7H), 4.67-4.14(m, 4H), 4.14(s, 2H), 2.88(d, J = 
5.0 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 136.8, 134.2, 132.8, 131.4, 130.2, 129.6, 129.4, 
128.8. Anal. Calcd. for C17H16Cl3NO•HCl•EtOAc: C, 52.41; H, 5.24; N, 2.91. Found: C, 52.41 H, 
5.35; N, 3.61. 
 
N-Methyl-3-(3,4-dichlorophenyl)-3-(3,4-dichlorophenyl)methoxyazetidine 
hydrochloride (31i, ANT-106) 
General Procedure C. The product was obtained as a white solid (57%); mp 176.2-178.9 oC; 
1H NMR (400 MHz, DMSO-d6): δ 7.13-7.31(m, 6H), 4.51(m, 4H), 4.19(s, 2H), 2.86(s, 3H); 13C 
(100 MHz, CDCl3): δ 136.4, 135.9, 134.4, 134.0, 133.0, 132.6, 131.7, 130.9, 129.6, 128.7, 
127.9, 127.0, 126.6, 126.0, 65.7, 64.6, 43.9. Anal. Calcd. for C17H15Cl4NO•HCl: C, 47.75; H, 
3.77; N, 3.28. Found: C, 47.50 H, 3.94; N, 3.18. 
 
N-Methyl-3-phenyl-3-(4-fluorophenyl)methoxyazetidine hydrochloride (31j, ANT-199)  
General Procedure C. The product was obtained as a white solid (42%); mp 177.8-180.3 oC; 
1H NMR (400 MHz, DMSO-d6) δ 7.55 – 7.31 (m, 7H), 7.13 (t, J = 8.7, 2H), 4.65 – 4.13 (m, 4H), 
4.13 (s, 2H), 2.89 (d, J = 30.8, 3H). 13C NMR (100 MHz, DMSO-d6) δ 163.5, 161.1, 157.0, 
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134.2, 130.7, 130.6, 129.5, 129.5, 127.2, 115.8, 115.6, 115.4, 77.6, 65.5, 64.0. Anal. Calcd. for 
C17H18NOF•HCl: C, 66.34; H, 6.22; N, 4.55. Found: C, 66.1; H, 6.42; N, 4.27. 
 
N-Methyl-3-phenyl-3-(2-fluorophenyl)methoxyazetidine oxalate (31k, ANT-138)  
General Procedures C and D. The product was obtained as a tan solid (20%); mp 149.0-
152.8 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.61 – 7.29 (m, 7H), 7.22 – 7.07 (m, 2H), 4.49 – 
4.18 (m, 4H), 4.18 (s, 2H), 2.90 (d, J = 9.8 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 164.5, 
137.9, 131.3, 130.6, 129.6, 129.4, 127.2, 125.1, 124.8, 115.6, 115.6, 77.5, 64.3, 60.07, 55.9. 
Anal. Calcd. for C17H18NOF•C2H2O4: C, 63.15; H, 5.85; N, 3.88. Found: C, 63; H, 5.89; N, 3.67. 
 
N-Methyl-3-phenyl-3-(3,4-difluorophenyl)methoxyazetidine oxalate (31l, ANT-139)  
General Procedures C and D. The product was obtained as a tan solid(21%); mp 124.1-
126.9 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.38 (d, J = 7.4 Hz, 12H), 4.37 – 3.91 (m, 6H), 2.92 
(s, 2H), 1.96 (d, J = 1.0 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 171.1, 164.2, 142.4, 137.7, 
129.6, 129.4, 129.0, 128.6, 127.3, 126.1, 71.2, 68.7, 65.3, 64.4, 64.0, 42.2, 25.4. Anal. Calcd. 
for C17H17F2NO • C2H2O4: C, 60.16; H, 5.05; N, 3.69. Found: C, 60.12; H, 5.14; N, 3.57. 
 
N-Methyl-3-(4-fluorophenyl)-3-phenylmethoxyazetidine hydrochloride (31m, ANT-158) 
General Procedure C. The product was obtained as a white solid (24%); mp 197.3-197.6 oC; 
1H NMR (400 MHz, DMSO-d6) δ 7.54 (s, 2H), 7.34 – 7.26 (m, 7H), 4.43 (s, 4H), 4.13 (s, 2H), 
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2.88 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 164.1, 161.6, 137.9, 134.5, 129.8, 129.7, 128.9, 
128.5, 128.3, 116.4, 116.1, 76.7, 66.2, 64.2. Anal. Calcd. for C17H18FNO•HCl: C, 65.42; H, 
5.83; N, 4.77. Found: C, 65.05; H, 6.00; N, 4.51. 
 
N-Methyl-3-(4-fluorophenyl)-3-(4-fluorophenyl)methoxyazetidine oxalate (31o, ANT-
156)  
General Procedures C and D. The product was obtained as a tan solid (23%); mp 112.3-
114.7 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.52 (dd, J = 16.7 Hz, J = 11.9 Hz, 4H), 7.37 – 7.14 
(m, 4H), 4.18 (s, 4H), 4.18 (s, 2H), 2.85 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 164.3, 161.6, 
134.3, 131.3, 130.7, 129.8, 129.7, 129.4, 127.2, 125.1, 116.3, 116.1, 115.9, 115.7, 77.1, 68.7, 
64.4, 60.1. Anal. Calcd. for C17H17F2NO•C2H2O4: C, 60.16; H, 5.05; N, 3.69. Found: C, 59.99; H, 
5.20; N, 3.50. 
 
N-Methyl-3-(4-fluorophenyl)-3-(4-fluorophenyl)methoxyazetidine hydrochloride (31n, 
ANT-147) 
General Procedure C. The product was obtained as a tan solid (19%); mp 173.4-177.0 oC; 
1H NMR (400 MHz, DMSO-d6) δ 7.74 – 7.00 (m, 8H), 4.75 – 4.16 (m, 6H), 4.11 (s, 2H), 2.83 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 164.1, 163.5, 161.6, 161.1, 155.3., 134.2, 130.7, 130.66, 
129.8, 116.4, 116.2, 115.7, 65.5, 64.2. Anal. Calcd. for C17H17F2NO•HCl: C, 62.67; H, 5.57; N, 
4.30. Found: C, 62.72; H, 5.64; N, 4.56. 
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N-Methyl-3-(4-fluorophenyl)-3-(3,4-difluorophenyl)methoxyazetidine hydrochloride 
(31p, ANT-157) 
General Procedure C. The product was obtained as a pale green solid (26%); mp 186.0-
187.0 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.57 – 7.48 (m, 4H), 7.38 – 7.30 (m, 3H), 7.17 (s, 
1H), 4.52 – 4.16 (m, 4H), 4.15 (d, J = 13.6, 2H), 2.85 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 
164.1, 161.6, 150.6, 135.8, 134.3, 129.7, 125.1, 117.7, 116.4, 116.2, 101.2, 95.7, 75.8, 65.0, 
64.1. Anal. Calcd. for C17H16F3NO•HCl: C, 59.39; H, 4.98; N, 4.07. Found: C, 59.15; H, 5.01; N, 
3.99. 
 
N-Methyl-3-(3,4-difluorophenyl)-3-phenylmethoxyazetidine oxalate (31q, ANT-173)  
General Procedures C and D. The product was obtained as a tan solid (4%); mp 110.0-111.4 
oC; 1H NMR (400 MHz, DMSO-d6) δ 7.53 – 7.27 (m, 8H), 4.56 – 4.25 (m, 4H), 2.94 (s, 2H), 
2.49 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 164.1, 137.8, 129.0, 128.5, 128.4, 125.8, 125.4, 
124.6, 66.7, 66.6, 66.5, 64.7, 64.6, 55.9, 51.0, 49.9, 49.6. Anal. Calcd. for 
C17H17F2NO•C2H2O4•1H2O: C, 57.43; H, 5.33; N, 3.5. Found: C, 57.55; H, 5.44; N, 3.41. 
 
N-Methyl-3-(3,4-difluorophenyl)-3-(4-fluorophenyl)methoxyazetidine oxalate (31r, 
ANT-174)  
General Procedures C and D. The product was obtained as a white solid (12%); mp 133.4-
135.2 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.53 (s, 1H), 7.33 (s, 4H), 7.12 (s, 2H), 4.55-4.23 
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(m, 6H), 2.90 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 164.2, 163.5, 161.1, 134.0, 130.7, 
130.6, 125.8, 125.2, 119.4, 119.2, 115.8, 115.6, 75.0, 65.8, 64.2. Anal. Calcd. for 
C17H16F3NO•C2H2O4•1½H2O: C, 53.79; H, 4.96; N, 3.30. Found: C, 53.55; H, 4.76; N, 3.40. 
 
N-Methyl-3-(3,4-difluorophenyl)-3-(2-fluorophenyl)methoxyazetidine oxalate (31s, 
ANT-175)  
General Procedures C and D. The product was obtained as a white solid (11%); mp 128.4-
131.4 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.52-7.12 (m, 7H), 4.88 – 3.96 (m, 6H), 2.90 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 164.3, 131.2, 130.8, 127.2, 125.7, 125.3, 125.1, 124.7, 
119.4, 119.3, 115.9, 115.7, 75.1, 64.0, 60.4. Anal. Calcd. for C17H16F3NO•C2H2O4 : C, 57.43; H, 
4.57; N, 3.53. Found: C, 57.15; H, 4.77; N, 3.30. 
 
N-Methyl-3-(3,4-difluorophenyl)-3-(3,4-difluorophenyl)methoxyazetidine oxalate (31t, 
ANT-176)  
General Procedures C and D. The product was obtained as a tan solid (17%); mp 137.6-
140.7 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.53 (s, 1H), 7.39 – 7.16 (m, 5H), 4.57 – 4.24 (m, 
6H), 2.90 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 163.7, 148.6, 135.6, 127.1, 125.8, 125.2, 
119.4, 119.3, 118.0, 117.8, 117.6, 117.4, 75.1, 65.3, 64.2. Anal. Calcd. for 
C17H15F4NO•C2H2O4•1½H2O: C, 53.79; H, 4.96; N, 3.30. Found: C, 53.89; H, 4.30; N, 3.26. 
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N-Methyl-3-phenyl-3-(4-(trifluoromethyl)phenyl)methoxyazetidine hydrochloride (31u, 
ANT-225)  
General Procedure C. The product was obtained as a white solid (28%); mp 131.3-134.0 oC; 
1H NMR (400 MHz, DMSO-d6) δ 7.96 – 6.72 (m, 9H), 4.46 (s, 2H), 4.32 – 4.16 (m, 2H), 3.43 (s, 
2H), 2.89 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 142.9, 137.8, 129.6, 129.5, 128.9, 128.9, 
128.6, 128.5, 127.2, 126.1, 125.6, 115.5, 75.8, 74.8, 68.9, 65.4, 64.0. Anal. Calcd. for 
C18H18F3NO•HCl: C, 60.42; H, 5.35; N, 3.91. Found: C, 60.11; H, 5.54; N, 3.78. 
 
N-Methyl-3-phenyl-3-(2,4-bis(trifluoromethyl)phenyl)methoxyazetidine oxalate (31v, 
ANT-217)  
General Procedures C and D. The product was obtained as a white solid (33%); mp 116.9-
117.7 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.46 (s, 8H), 4.54 – 4.26 (m, 6H), 2.95 (s, 3H). 13C 
NMR (100 MHz, DMSO-d6) δ 170.9, 163.6, 129.7, 129.5, 129.4, 127.3, 125.9, 125.7, 75.80, 
73.6, 66.8, 65.2, 64.6, 62.1, 58.4, 42.8. Anal. Calcd. for C19H16F6NO•C2H2O4 : C, 52.62; H, 4; N, 
2.92. Found: C, 5.44; H, 4.11; N, 2.88. 
 
N-Methyl-3-phenyl-3-(3,5-bis(trifluoromethyl)phenyl)methoxyazetidine hydrochloride 
(31w, ANT-218)  
General Procedure C. The product was obtained as a white solid (23%); mp 173.5-175.4 oC; 
1H NMR (400 MHz, DMSO-d6) δ 7.94 – 7.11 (m, 8H), 4.79 – 4.06 (m, 6H), 2.86 (s, 3H). 13C 
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NMR (100 MHz, DMSO-d6) δ 170.9, 141.7, 140.1, 139.9, 139.4, 137.8, 130.4, 129.6, 129.4, 
126.3, 122.0, 116.9, 115.8, 114.6, 112.2, 75.8, 65.2, 64.0, 21.5. Anal. Calcd. for 
C19H17F6NO•HCl: C, 53.59; H, 4.26; N, 3.29. Found: C, 53.41; H, 4.31; N, 3.20. 
 
N-Methyl-3-(4-trifluromethyl)phenyl-3-phenylmethoxyazetidine oxalate (31x, ANT-
184)  
General Procedures C and D. The product was obtained as a white solid (22%); mp 130.1-
132.3 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 2H), 7.94 – 7.14 (m, 9H), 4.46 – 4.14 (m, 
6H), 2.90 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 171.0, 163.3, 137.8, 129.0, 128.1, 128.5, 
128.3, 127.9, 127.4, 126.8, 126.4, 115.3, 66.4, 65.7, 64.2, 56.0, 42.3. Anal. Calcd. for 
C18H18F3NO•C2H2O4 : C, 58.39; H, 4.90; N, 3.40. Found: C, 58.03; H, 5.11; N, 3.35. 
 
N-Methyl-3-(4-trifluromethyl)phenyl-3-(4-(trifluoromethyl)phenyl)methoxyazetidine 
oxalate (31y, ANT-185)  
General Procedures C and D. The product was obtained as a white solid (19%); mp 183.4-
184.8 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.06 – 7.46 (m, 8H), 4.44 – 4.17 (m, 6H), 2.85 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 165.1, 142.9, 128.8, 128.6, 128.2, 127.8, 127.1, 126.8, 
126.3,  125.7,  123.6,  77.1, 68.6, 65.7,  64.1, 42.6. Anal. Calcd. for C19H17F6NO•C2H2O4: C, 
52.62; H, 4; N, 2.92. Found: C, 52.22; H, 4.3; N, 2.75. 
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N-Methyl-3-(4-trifluromethyl)phenyl-3-(2,4-bis(trifluoromethyl)phenyl)methoxy-
azetidine oxalate (31z, ANT-187)  
General Procedures C and D. The product was obtained as a white solid (34%); mp 182.9-
183.3 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.99 – 7.40 (m, 7H), 4.46 – 4.241 (m, 6H), 2.86 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 165.0, 142.7, 140.0, 139.8, 133.0, 131.8, 129.7 , 128.9, 
128.3, 127.2, 126.3, 125.3, 124.3, 123.3, 122.3, 77.3, 65.3, 64.1, 42.6 Anal. Calcd. for 
C20H16F9NO•C2H2O4•1H2O: C, 46.74; H, 3.51; N, 2.48. Found: C, 46.55; H, 3.65; N, 2.24. 
 
N-Methyl-3-(4-trifluromethyl)phenyl-3-(3,5-bis(trifluoromethyl)phenyl)methoxy-
azetidine oxalate (31aa, ANT-186)  
General Procedures C and D. The product was obtained as a white solid (30%); mp 114.6-
118.5 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.12 – 7.50 (m, 7H), 4.66 – 4.16 (m, 6H), 2.90 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 172.7, 163.7, 142.1, 132.7, 131.6,  128.4,  127.2, 126.3, 
123.4, 123.1, 115.6,  68.5, 63.94, 56.0, 42.3. Anal. Calcd. for C20H16F9NO•C2H2O4•1H2O: C, 
46.74; H, 3.57; N, 2.48. Found: C, 46.69; H, 3.55; N, 2.44. 
 
N-Methyl-3-(2,4-bis(trifluromethyl)phenyl)-3-phenylmethoxyazetidine hydrochloride 
(31bb, ANT-258)  
General Procedure C. The product was obtained as a brown solid (35%); mp 156.0-157.2 
oC; 1H NMR (400 MHz, DMSO-d6) δ 7.88 (m, 5H), 7.26 (s, 3H), 5.38 – 3.63 (m, 6H), 2.91 (s, 
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3H). 13C NMR (100 MHz, DMSO-d6) δ 165.3, 139.8, 137.7, 133.5, 131.2, 130.2, 128.9, 128.6, 
128.1, 126.3, 125.4, 123.9, 114.4, 112.0, 110.0, 77.5, 67.0, 63.9, 42.3.  
 
N-Methyl-3-(2,4-bis(trifluromethyl)phenyl)-3-(4-trifluoromethyl)phenylmethoxy-
azetidine hydrochloride (31cc, ANT-259)  
General Procedure C. The product was obtained as a yellow solid (23%); mp 167.9-169.4 
oC; 1H NMR (400 MHz, CDCl3) δ 7.51 (dt, J = 4.2 Hz, J = 2.3 Hz, 3H), 7.42 – 7.34 (m, 4H), 4.28 
– 4.12 (m, 6H), 1.98 (dd, J = 13.2 Hz,  J = 2.7 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 176.3, 
138.2, 129.3, 128.6, 126.3, 101.5, 69.3, 65.7, 43.3, 43.2, 29.9, 29.2, 29.1, 29.1, 26.0, 25.6.  
 
N-Methyl-3-(2,4-bis(trifluromethyl)phenyl)-3-(2,4-bis(trifluoromethyl)phenyl) 
methoxyazetidine oxalate (31dd, ANT-286)  
General Procedures C and D. The product was obtained as a brown solid (18%); mp oC; 1H 
NMR (400 MHz, DMSO-d6) δ 7.92 - 6.98 (m, 6H), 4.58 - 4.29 (m, 3H), 2.90 (s, 2H), 2.28 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 164.9, 141.3, 139.4, 138.9, 137.0, 132.7, 131.4, 130.3, 
129.0, 128.6, 127.3, 126.7, 125.3, 123.1, 64.4, 21.3, 19.2. 
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N-Methyl-3-(2,4-bis(trifluromethyl)phenyl)-3-(3,5-bis(trifluoromethyl)phenyl) 
methoxyazetidine oxalate (31ee, ANT-287)  
General Procedures C and D. The product was obtained as a yellow solid (24%); mp oC; 1H 
NMR (400 MHz, DMSO-d6) δ 7.92 (tt, J = 23.0 Hz, 11.5 Hz, 3H), 7.61 - 7.33 (m, 1H), 7.31 – 
6.90 (m, 2H), 4.45 (m, 6H), 2.89 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 172.7, 164.7, 141.8, 
139.4, 132.6, 130.4, 128.9, 128.5, 126.7, 125.3, 122.6, 121.7, 78.7, 64.9, 64.4, 64.0, 55.9.  
 
N-Methyl-3-(3,5-bis(trifluromethyl)phenyl)-3-phenylmethoxyazetidine hydrochloride 
(31ff, ANT-247)  
General Procedure C. The product was obtained as a tan solid (36%); mp 161.2-163.6 oC; 
1H NMR (400 MHz, DMSO-d6) δ 7.88 – 6.90 (m, 8H), 4.88 – 4.02 (m, 6H), 2.91 (s, 3H). 13C 
NMR (100 MHz, DMSO-d6) δ 172.6, 170.9, 145.7, 140.5, 137.8, 132.1, 128.8, 128.5, 128.3, 
127.2, 126.6, 126.1, 123.8, 123.4, 115.5, 77.3, 66.5, 63.9, 62.6. Anal. Calcd. for 
C19H17F6NO•HCl•1½ H2O: C, 50.39; H, 3.79; N, 3.09. Found: C, 50.68; H, 3.99; N, 2.6. 
 
N-Methyl-3-(3,5-bis(trifluromethyl)phenyl)-3-(4-(trifluoromethyl)phenyl)methoxy-
azetidine oxalate (31gg, ANT-238)  
General Procedures C and D. The product was obtained as a white solid (46%); mp 157.3-
160.0 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.81 – 7.45 (m, 7H), 4.41 (d, J = 95.6, 6H), 2.91 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 164.5, 161.9, 137.9, 131.3, 130.7, 129.6, 129.4, 129.0, 
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127.2, 126.1, 125.1, 124.9, 115.8, 115.6, 77.5, 75.8, 68.7, 64.3, 60.0, 42.5. Anal. Calcd. for 
C20H16F9NO•C2H2O4 : C, 47.29; H, 3.02; N, 2.63. Found: C, 47.01; H, 3.22; N, 2.47. 
 
N-Methyl-3-(3,5-bis(trifluromethyl)phenyl)-3-(2,4-bis(trifluoromethyl)phenyl) 
methoxyazetidine oxalate (31hh, ANT-248)  
General Procedures C and D. The product was obtained as a yellow solid(66%); mp 106.4-
108.1 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.23 – 6.78 (m, 6H), 4.64 – 3.96 (m, 4H), 2.30 (s, 
3H). 13C NMR (100 MHz, DMSO-d6) δ 165.2, 132.7, 132.0, 131.1, 130.9, 126.6, 126.3, 125.6, 
123.8, 115.6, 68.7, 65.1, 64.3, 21.5, 21.2, 21.1. Anal. Calcd. for C21H15F12NO•C2H2O4•1H2O: C, 
43.61; H, 3.02; N, 2.21. Found: C, 43.33; H, 3.02; N, 2.01. 
 
N-Methyl-3-(3,5-bis(trifluromethyl)phenyl)-3-(3,5-bis(trifluoromethyl)phenyl) 
methoxyazetidine oxalate (31ii, ANT-239)  
General Procedures C and D. The product was obtained as a off white solid (37%); mp 
125.6-128.4 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.20 – 6.90 (m, 6H), 4.74 – 4.11 (m, 6H), 
2.90 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 170.9, 164.0, 138.4, 132.1, 130.9, 130.5, 129.4, 
128.8, 127.2, 126.7, 126.4, 125.3, 123.9, 122.4, 121.9, 121.2, 114.5, 77.3, 63.9, 21.3. Anal. 
Calcd. for C21H15F12NO•C2H2O4 : C, 44.89; H, 2.78; N, 2.28. Found: C, 44.77; H, 3.02; N, 2.19. 
  
 95
Part II: Synthesis of 3,3-Diaryl Azetidines 
 
Abstract 
 
Diaryl heterocycles are known to have an important in place in pharmaceuticals. 
Many diaryl heterocycles are commercially used and studied for a variety of diseases and 
disorders. Traditional syntheses of diaryl heterocycles are accomplished in three to eight 
steps involving either time consuming steps or complication cyclizations from expensive 
starting materials. The novel synthesis described completes formation of 3,3-
diarylazetidines, 3,3-diarylpyrrolidines, and 4,4-diarylpiperidines in two steps from the 
respective N-Boc-ketones in moderate to good yield. These diarylation syntheses have been 
accomplished in both symmetrical and asymmetrical aryl additions.  
Key Words: Diaryl heterocycles, Friedel-Crafts Alkylation, Azetidine, Pyrrolidine, Piperidine 
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Introduction 
 
Nitrogen containing ring systems are widely used throughout medicinal chemistry 
in everything from illicit drugs to penicillin. Molecules such as 3,3-diaryloxindoles in 
particular exhibit antibacterial, antiprotazoal and antiinflamatory activities. 3,3-diphenyl 
derivatives of succinimides and hydantoins display anticonvulsant activity. In all cases the 
3,3-diaryl analogs are shown to be more biologically important. The synthesis of 3,3-
diphenylpyrrolidines known in literature include those starting from diarylacetonitrile 
(39), 4-phenoxy, benzophenone (38), 4-bromo-2,2-diphenylbutylamine hydrochloride 
(40), or 4-amino-3,3-diphenylbutan-1-ol hydrochloride (41).87-91 
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4.1 Pharmaceutical Examples of Diaryl Heterocycles 
 
 There are several examples of diaryl heterocyclic systems both in drug discovery 
and on the market. 3,3-Diaryloxindoles (42 and 43) have been used as laxatives, the β-
lactam azetidine (44) is known to have sedative and hypnotic effects.87 The imidizolidine 
(45) is currently on the market and used as an anticonvulsant and azepane (46) analogs 
are patented as having serotonin effects. Synthesis of these diaryl heterocyclic compounds, 
however, is highly involved and either takes multiple time consuming steps or starts from 
expensive starting materials.87-93 
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4.2.1 Synthesis of 3,3-Diarylpyrrolidine from Benzophenone 
 
Starting from benzophenone, 3,3-diphenylpyrrolidine was synthesized in seven 
steps.87 The condensation of benzophenone was completed using cyanoacetate under 
Knoevenagel conditions then converted to 2,2-diphenylsuccinic acid via the dicyanoester 
(49). Diphenylsuccinic acid was cyclized to the anhydride using acetyl chloride and 
subsequent treatment with benzylamine gave the succinimic acid (52). It was then re-
cyclized by refluxing in acetic anhydride and then reduced using sodiumborohydride to 
afford 3,3-diphenylpyrrolidine (54).87  
 
 
Scheme 11: Synthesis of 3,3-diphenylpyrrole from benzophenone 
 
 
As exhibited in Scheme 11 this complex synthesis is completed in seven steps, and 
three recrystallizations that proved to be very timely and gave an overall 58% yield.  While 
employing very inexpensive reagents, the reaction takes upwards of 131 hours to complete, 
which is excessive in terms of pharmaceutical development for both academia and industry 
alike.87  
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4.2.2 Synthesis of 3,3-Diarylpyrrolidine from Diphenylbutylamine  
 
 Scheme 12 details the synthetic route for the synthesis of 3,3-diarylpyrrolidine 
using diphenylbutylamine as an intermediate. Reacting 3,3-diphenyl-5-methyl-2-furanone-
imine (55) with ethylmagnesium bromide followed by treatment of and ice cold 
ammonium chloride solution afforded 2,5-dimethyl-3,3-diphenyltetrahydrofuran-2-amine 
(56). The 2-amino tetrahydrofuran was then reduced with lithium aluminum hydride 
producing 6-ethoxy-4,4-diphenylhexan-3-amine (57). The hydrochloride then underwent 
pyrolysis to give the cyclized 3,3-diarylpyrrolidine (58). 90  
  
 
Scheme 12: Synthesis of 3,3-diarylpyrrolidine from diphenylbutylamine 
 
 
 While this synthesis is completed in three steps with only three recrystallizations, 
the 3,3-diphenyl-5-methyl-2-furanone-imine starting material is a very expensive.90 At 
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$100 for 50mg this route is not feasible for extensive studies. Commercial sources, also, do 
not sell substituted diaryl-furanone-imines therefore only the formation of 3,3-diphenyl 
analogs can be synthesized from commercially available materials. This significantly 
diminishes the range of possible pharmacophores. In order to synthesize an analog with 
substitution on the aryls, the substituted furanone-imine starting material would need to 
be synthesized which would increase reaction length, time, and materials needed. 
 
4.2.3 Synthesis of 3,3-Diarylpyrrolidine from Diphenylacetonitrile 
 
Synthesis of 3,3-diphenylpyrrolidine from diphenylacetonitrile can be completed in 
three steps with three recrystallizations. The intermediate carbothxylalkyl-
phenylacetonitrile (60) was synthesized by the alkylation of diphenylacetonitrile with 
carbethoxybromide and sodium amide. These esters were then hydrogenated with Raney 
nickel to form 3,3-diarylpyrrolidinone (61), which was then reduced with lithium 
aluminum hydride to produce 3,3-diarylpyrrolidine (54).88 
 
 
 
Scheme 13: Synthesis of 3,3-diarylpyrrolidine from diphenylacetonitrile 
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Of the three syntheses seen thus far, Scheme 13 is the first to depict the ability to 
form heterocycles of various sizes. By simply changing the alkylbormide used, the ring 
system can be expanded or contracted from the pyrrolidine depicted above. This reaction 
also uses inexpensive reagents and produces 3,3-diarylpyrrolidine in good yield.88 While 
diphenylacetonitrile is moderately priced and commercially available, that is not the case 
for substituted diarylacetonitriles. Typical commercial chemical retailers such as Sigma-
Aldrich or Acros Organics do not carry any substituted diarylacetonitriles in their 
inventory. Therefore, similar to reactions from furanone-imine as the starting material, the 
synthesis of a substituted diarylacetonitrile would first have to be completed.  
 
4.2.4 Synthesis of 4,4-Diarylpiperidines from 4-Piperidinone 
 
 Recently, Klump reported that N-substituted-4,4-diarylpiperidines can be 
synthesized from N-substituted-4-piperidinone using an excess of triflic acid.93  This work 
was expanded to include syntheses starting from tropanones and quinuelidones. These 
compounds were synthesized in one step as seen in Scheme 14.93  
 
Scheme 14: Synthesis of 4,4-diphenylpiperidine from 4-piperidinone 
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Table 4: Results of Diaryl Formation 
Starting Material Product Yield 
62a 
 
63a 
 
99% 
62b 
 
63b 
 
99% 
64 
 
65 
 
80% 
66a 
 
67a 
 
85% 
66b 
 
67b 
 
Not 
Provided 
 
Each Starting material was reacted with 6 equiv. of TfOH and excess benzene or 
chlorobenzene. 
 
 
Table 4 provides percent yields for the formation of diaryl products. As seen in the 
table, each of these products was produced in good to excellent yield when reacted with six 
equivalents of triflic acid and excess benzene. N-substituted piperidines were produced in 
quantitative yield for the formation of 4,4-diphenylpiperidine, 63a and 63b. Moderate 
yields where seen for the formation of N-methyl-4,4-diphenyl-tropane, 67a and N-ethyl -
3,3-diphenylpiperidine, 65.93  
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Klump also attempted synthesis of an asymmetrical 4,4-diaryl-piperidinone, as seen 
in Scheme 15. Unfortunately, multiple products were seen. When reacting intermediate 68 
with 6 equivalents of triflic acid and chlorobenzene products 63a, 69, and 70 were seen in 
a ratio of 1.0:9.3:12.2.93 Therefore, synthesis of asymmetrical heterocycles using this 
method is not viable. 
 
 
Scheme 15: Attempted formation of asymmetrical piperidine 
 
 
4.3 New Methodology 
 
 After examining formation of 3,3-diarylpyrrolidines from benzophenone, 
diphenylbutylamine, diphenylacetonitrile, and piperidinone it is evident that a novel facile 
synthesis of substituted diarylheterocyclic systems is needed. All of the previously reported 
syntheses also either ignore or were unsuccessful as isolating in good yield asymmetrically 
substituted aryl moieties.  
 It was recently determined that a diarylated piperidine could be synthesized using 
aluminum chloride via Scheme 16. This synthesis gives the diarylation formation in one 
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step from 4-(4-bromophenyl)4-piperidinol. It provides the ability for substituted aryl 
moieties as well as an asymmetrical system. However, the patent that described this work 
as an intermediate only provided the single example and did not evaluate the scope and 
versatility of this methodology.94  
 
 
 
Scheme 16: Asymmetrical diarylation using AlCl3 
 
  
Taking into account the previously reported optimized experimental method for 
formation of N-Boc-3-aryl-3-azetidinol, it was envisaged that asymmetrical diarylation 
could be achieved for four, five, and six membered heterocycles in two steps from the Boc-
protected ketone. Examining the same methodology in a tropanol system was also thought 
to be attractive for purposes of biological evaluation at various monoamine transporters. It 
was also assumed that Boc deprotection would easily be achieved in the same arylation 
step utilizing aluminum chloride. The retrosynthetic approach for the formation of 3,3-
diarylazetidine is seen in Figure 13.  
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Figure 13: Retrosynthetic approach to the formation of 3,3-diarylazetidines 
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Results and Discussion 
 
 The reported 4,4-diarylpiperidine was a robustly stable compound. It was of 
interest to see if similar methodologies could be employed on azetidine, pyrrolidine and 
tropane scaffolds. The ability to easily synthesize various diaryl heterocylic ring systems 
quickly would aid in determination of pharmacophore scaffolds and drug discovery.  
 
5.1 Proposed Mechanism of Formation of 3,3-Diarylheterocycles 
 
 The novel synthesis of 3,3-diarylheterocycles utilizes aluminum chloride as its 
major reagent. Aluminum chloride is known as a Lewis acid and is typically used in Friedel-
Crafts alkylation reactions. It was postulated that in our reaction, aluminum chloride first 
would remove the protecting group by coordinating to the carbamate oxygen atoms to 
form the intermediate seen in Scheme 17. This intermediate then breaks down to form 
isobutene and carbon dioxide.  
 
Scheme 17: Proposed Boc deprotection using AlCl3 
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The reaction then undergoes a Friedel-Crafts alkylation. Aluminum chloride acts as an 
electron lone pair acceptor and forms AlCl3OH as well as a strong electrophilic carbocation 
on the ring structure as seen in Scheme 18.  
 
Scheme 18: Proposed Friedel-Crafts Alkylation 
 
5.2 Synthesis of Symmetrical and Asymmetrical 3,3-Diarylazetidines 
 
 Synthesis of 3,3-diaryl azetidine analogs was completed in two steps with moderate 
to good yield. As seen in Scheme 19 the N-Boc-3-aryl-azetidinol intermediate 28 was 
synthesized under previously reported conditions by reacting N-Boc-3-azetidinone 27 with 
butyllithium and the intended arylbromide. Column chromatography was utilized before 
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moving onto the next step of the synthesis. The N-Boc-3-aryl-azetidinol 28 was then 
treated with aluminum chloride and the desired benzene derivative to achieve 3,3-
diarylazetidine (73). This reaction took place in two hours at 0oC.  The Boc protecting 
group was removed during this reaction as well, which allowed the crude mixture to be 
freebased and the product to be isolated as the oxalate salt. Formation of the final product 
as the oxalate salt eliminated the need for an additional purification step.  
 
 
Scheme 19: Synthesis of 3,3-Diarylazetidine oxalate 
 
As seen in Table 5, symmetrical and asymmetrical diaryl substitution on the 
azetidine ring system was completed in good yield (53-84%).  Aryl electron withdrawing 
and donating substituents were tolerated by the reaction conditions. A slight increase in 
percent yield was seen when adding chlorobenzene to the azetidine system. The exception 
is compound 73n, which had the highest observed yield at 84%. Adding fluorobenzene to 
the system produced lower yields (53-60%). In the case of activating groups on the aryl 
ring, toluene was added in higher yield than methoxybenzene, 62-84% yield and 62-73% 
yield, respectively.   
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Table 5: Percent Yield for 3,3-Diarylazetidine 
 
Compound Experiment X Y % Yield 
73a ANT - 243 H H 71% 
73b ANT - 267 H Cl 80% 
73c ANT - 268 H F 60% 
73d ANT - 330 H CH3 71% 
73e ANT - 331 H OMe 62% 
73f ANT - 289 Cl H 69% 
73g ANT - 290 Cl Cl 81% 
73h ANT - 318 Cl F 53% 
73i ANT - 291 Cl CH3 62% 
73j ANT - 319 Cl OMe 63% 
73k ANT - 332 F H 63% 
73l ANT - 333 F Cl 74% 
73m ANT - 293 F F 59% 
73n ANT - 313 F CH3 84% 
73o ANT - 334 F OMe 73% 
 
 
5.3 Synthesis of 4,4-Diarylpiperidine, 3,3-Diarylpyrrolidine, and 4,4-
Diaryltropane 
 
 4,4-diarylpiperidine was synthesized in the same manner as 3,3-diaryl azetidine, 
depicted in Scheme 20. Commercially available N-Boc-4-piperidinone (76) was reacted 
with butyllithium and bromobenzene to form N-Boc-4-phenyl-piperidinol (77). The 
tertiary alcohol intermediate was purified by column chromatography and then reacted 
with aluminum chloride and the corresponding benzene to form 4,4-diarylpiperidine 
analogs (78). The crude mixture was freebased and the product isolated as an oxalate salt. 
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Scheme 20: Synthesis of 4,4-Diarylpiperidine 
  
 
N-Boc-3-pyrrolidinone (80) is not commercially available due to rapid 
decomposition. Therefore, N-Boc-3-pyrrolidinol was oxidized using Dess-Martin reagent to 
form N-Boc-3-pyrrolidinone (80), which was then reacted with butyllithium and 
bromobenzene to form N-Boc-3-phenyl-3-pyrrolidinol (81). Purification was completed by 
column chromatography and pure 81 underwent the established Friedel-Crafts alkylation, 
and formation of the oxalate salt to generate 3,3-diarylpyrrolidine analogs (82) as seen in 
Scheme 21.    
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Scheme 21: Formation of 3,3-Diarylpyrrolidine 
 
 N-Boc-nortropinione is commercially available however, due to its exorbitant price,  
N-ethoxycarbonyl-nortropinone (84) was synthesized instead by treating nortropinone 
(83) with ethylchloroformate under basic conditions. The protected tropinone was purified 
and then reacted under the established conditions to form 4,4-diaryltropane analogs as 
represented in Scheme 22. 
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Scheme 22: Synthesis of 4,4-Diaryltropane 
 
 
 Table 6 shows the yields for reacting N-Boc-4-phenyl-piperidinol (77), N-Boc-3-
phenyl-3-pyrrolidinol (81) and N-ethoxycarbonyl-4-phenyl-4-tropanol (85) were reacted 
with benzene, chlorobenzene, methoxybenzene and toluene.  
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Table 6: Percent Yields for Diarylation of Piperidine, Pyrrolidine, and Tropane analogs 
 
Compound Experiment Ring System X Y % Yield 
78a ANT - 312 Piperidine H H 51% 
78b ANT - 320 Piperidine H Cl 60% 
78c ANT - 329 Piperidine H OMe 72% 
78d ANT - 321 Piperidine H CH3 79% 
82a ANT - 339 Pyrrolidine H H 44% 
82b ANT - 340 Pyrrolidine H Cl 46% 
82c ANT - 341 Pyrrolidine H OMe 41% 
82d ANT - 342 Pyrrolidine H CH3 54% 
86a ANT - 325 Tropane H H 6% 
86b ANT - 326 Tropane H Cl 12% 
86c ANT - 327 Tropane H OMe NP 
86d ANT - 328 Tropane H CH3 11% 
 
 
 Both 4,4-diarylpiperidine (78) analogs demonstrate similar results to that seen in 
the azetidine series. Moderate to good yields were seen for the formation of 4,4-
diarylpiperidine analogs with 51-79% yield. The addition of toluene and methoxybenzene 
had the highest percent yields seen for the piperidine analogs (79% yield, 72% yield), 
which was to be expected, since toluene and methoxybenzene are mildly electron rich they 
facilitate electrophilic addition to the heterocylic scaffolds.  
 The 3,3-diarylpyrrolidine analogs (82) were synthesized in moderate yield, 41-54%. 
Analog 3-phenyl-3-(p-methylphenyl)pyrrolidine (82d) had the highest yield at 54% while 
3-phenyl-3-(p-methoxyphenyl)pyrrolidine (82c) had the lowest yield at 41%.  
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 Tropane analogs (86) displayed very poor yields, with 4-phenyl-4(p-
methoxyphenyl)tropanes (86c) having no product formation at all. These results were 
somewhat expected. It is probable that deprotection occurs first leaving the free amine. The 
formation of the carbocation at the 4 position leaves the opportunity for the free amine to 
attack and form a tricyclic system (88) as seen in Figure 14. This tricyclic system leaves no 
room for aryl addition. Though the tricycle, 88, was not isolated and identified as a side 
product, this isomer is known to occur in literature when a free amine and carbocation at 
C-4 are present in the tropane system.95  
 
 
Figure 14: Formation of tricylclic tropanes cation 
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Conclusions 
 
A novel two-step synthesis for the formation of 3,3-diarylheterocycles been 
established. Diaryl heterocylic formation can be achieved via a Friedel-Crafts alkylation 
from 3-aryl-azetidinol, 3-aryl-3-pyrollidinol, and 4-aryl-4-piperidinol. This synthesis is 
facile and efficient for the formation of both symmetrical and asymmetrical aryl 
substituents.  Formation of 3,3-diarylazetine, 4,4-diarylpiperidine analogs were 
synthesized in moderate to good yields, 53-84%. Azetidine analog 73n, 3-fluoropheyl-3-
(methylphenyl)azetidine had the highest yield at 84%. Of the piperidine series, 78d 4-
phenyl-4-(methylphenyl)piperidine had the highest yield at 79% yield. The 3,3-
diarylpyrrolidine analogs were synthesized in moderate yields, 41-54% with 3-phenyl-3-
(methylphenyl)pyrrolidine (82d) having the highest percent yield. Scope and versatility of 
this synthetic scheme is limited to date. Further evaluation including heterocyclic addition 
as well as a variety of substituted aryl addition, should be completed.  
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Experimental 
 
General Information 
Chemicals were purchased from Sigma-Aldrich Chemical Co., Oakwood Products Inc., 
and VWR International LLC and used as received or otherwise noted. Anhydrous solvents 
were purchased from EMD Millipore and were used under nitrogen without any further 
purification. Chromatography refers to column chromatography on silica gel (Silica Gel 60Å, 
230-400 mesh). Reported melting points are uncorrected. 1H NMR (400 MHz) and 13C NMR 
(100 MHz) were recorded on a Varian-400 MHz nuclear magnetic resonance spectrometer 
at ambient temperature in DMSO-D6.  1H NMR chemical shifts are reported as δ values 
(ppm) relative to tetramethylsilane.  13C NMR chemical shifts are reported as δ values 
(ppm) relative to DMSO-D6 (39.5 ppm). 
Solvent acronyms – Tetrahydrofuran (THF), Dichloromethane (DCM), Deionized 
water (DI). 
Preparation of N-Ethoxycarbonyl-nortropinone (84) 
 3-Tropinone (1 equiv.), potassium carbonate (0.05 equiv.) and ethylchloroformate 
(5 equiv.) were dissolved in dry toluene (15 mL) and the mixture heated to 110 oC 
overnight. The solvent was removed under reduced pressure and the oil partitioned 
between DCM and DI (15 mL each). The aqueous layer was extracted with DCM (3 x 10 mL), 
washed with brine (2 x 10  mL) and dried over anhydrous sodium sulfate. The solvent was 
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removed under reduced pressure and the oil purified by column chromatography (30% 
ethyl acetate:hexanes) to afford 84 as a colorless oil (57%); 1H NMR (400 MHz, CDCl3) δ 
4.12 – 4.02 (m, 2H), 4.00 – 3.93 (m, 1H), 2.53 (s, 2H), 2.27 – 2.15 (m, 2H), 1.96 (d, J = 3.0 Hz, 
2H), 1.90 – 1.88 (m, 1H), 1.55 (d, J = 6.9 Hz, 2H), 1.20 – 1.12 (m, 3H). 
 
Preparation of N-Ethoxycarbonyl-4-phenyl-4-tropanol (85) 
Bromobenzene (3 equiv.) was dissolved in anhydrous THF and cooled to -78 °C for 
10 minutes. n-butyllithium (2.5M, 3 equiv.) was added and the reaction stirred for 1 hour 
under nitrogen. N-Ethoxycarbonyl-4-phenyl-4-tropanol (1 equiv.) was dissolved in 
anhydrous THF, and added via syringe to the reaction. The mixture was stirred overnight 
to room temperature. The reaction was quenched with 10% NH4Cl, extracted with diethyl 
ether (3 x 15 mL), washed with brine (15 mL), and dried over anhydrous sodium sulfate, 
and the solvent removed under reduced pressure. The crude oil was purified by column 
chromatography (30% ethyl acetate:hexanes) to afford 85 as a while solid (57%); mp 90.7 - 
92.4 oC; 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.34 (m, 2H), 7.28 (dd, J = 10.5 Hz, J = 4.9 Hz, 
2H), 7.17 (dd, J = 8.1 Hz, 6.4, 1H), 4.33 (s, 2H), 4.15 – 4.06 (m, 2H),  2.44 – 2.17 (m, 4H), 1.95 
– 1.77 (m, 4H), 1.25 (d, J = 7.1 Hz, 3H). 
 
Preparation of N-Boc-3-pyrrolidinone (80) 
N-Boc-3-pyrrolidinol (79) (1 equiv.) and Dess-martin reagent (3 equiv.) was 
dissolved in 15 mL DCM. The reaction was stirred at room temperature for 3 hours. The 
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reaction was quenched with 15mL of DI, then extracted with DCM (3 x 10 mL), washed 
with brine (2 x 10 mL) and dried over anhydrous sodium sulfate. The clear oil was purified 
by column chromatography (30% ethyl acetate:hexanes) to afford 80 as a colorless oil 
(72%). 1H NMR (400 MHz, CDCl3) δ 3.63 (dd, J = 14.7 Hz, J = 6.7 Hz, 4H), 2.46 (t, J = 7.8 Hz, 
2H), 1.35 (s, 9H). 
 
Preparation of N-Boc-3-phenyl-3-pyrrolidinol (81) 
 Bromobenzene (3 equiv.) was dissolved in anhydrous THF and cooled to -78 °C for 
10 minutes. n-butyllithium (2.5M, 3 equiv.) was added and the reaction stirred for 1 hour 
under nitrogen. N-Boc-3-pyrrolidinone (80) (1 equiv.) was dissolved in anhydrous THF, 
and added via syringe to the reaction. The mixture was stirred overnight to room 
temperature. The reaction was quenched with 10% NH4Cl, extracted with diethyl ether (3 x 
15 mL), washed with brine (15 mL), and dried over anhydrous sodium sulfate, and the 
solvent removed under reduced pressure. The crude oil was purified by column 
chromatography (30% ethyl acetate:hexanes) to afford 81 as a while solid (30%); mp 133.3 
- 134.8 oC; 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 6.6 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.31 
(ddd, J = 7.3 Hz, J =  3.7 Hz, J =  1.2 Hz, 1H), 3.81 – 3.53 (m, 4H), 2.41 – 2.11 (m, 2H), 2.03 (d, 
J = 3.4 Hz, 1H), 1.47 (d, J = 8.4 Hz, 9H). 
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Preparation of N-Boc-4-phenyl-4-piperidinol (77) 
 Bromobenzene (3 equiv.) was dissolved in anhydrous THF and cooled to -78 °C for 
10 minutes. n-butyllithium (2.5M, 3 equiv.) was added and the reaction stirred for 1 hour 
under nitrogen. N-Boc-3-pyrrolidinone (1 equiv.) was dissolved in anhydrous THF, and 
added via syringe to the reaction. The mixture was stirred overnight to room temperature. 
The reaction was quenched with 10% NH4Cl, extracted with diethyl ether (3 x 15 mL), 
washed with brine (15 mL), and dried over anhydrous sodium sulfate, and the solvent 
removed under reduced pressure. The crude oil was purified by column chromatography 
(30% ethyl acetate:hexanes) to afford 77 as a while solid (30%); mp 110.2 - 111.8 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.44 (d, J = 7.7 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.23 (d, J = 7.1 Hz, 
1H), 3.96 (s, 2H), 3.21 (s, 2H), 1.93 (s, 2H), 1.69 (d, J= 12.6 Hz, 2H), 1.44 (s, 9H). 
 
General Procedure A: Preparation of 1-Boc-3-arylazetidin-3-ols (34) 
 Halogenated bromobenzene (3 equiv.) was dissolved in anhydrous THF and cooled 
to -78 °C for 10 minutes. n-butyllithium (2.5M, 3 equiv.) was added and the reaction stirred 
for 1 hour under nitrogen. 1-Boc-3-azetidinone (27) (1 equiv.) was dissolved in anhydrous 
THF, and added via syringe to the reaction. The mixture was stirred overnight to room 
temperature. The reaction was quenched with 10% NH4Cl, extracted with diethyl ether (3 x 
15 mL), washed with brine (15 mL), and dried over anhydrous sodium sulfate, and the 
solvent removed under reduced pressure. The crude oil was purified by column 
chromatography (30% ethyl acetate:hexanes) to afford 34a, 34b, and 34d. 
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1-Boc-3-phenyl-3-azetidinol (34a) 
General Procedure A. The azetidinol was obtained as a pale yellow solid (94%); mp 85.3-
87.8 oC; 1H NMR (400MHz, CDCl3): δ 7.49(d, J = 8, 2H), 7.42-7.38(m, 2H), 7.33-7.30(m, 1H), 
4.27(d, J = 9.2 Hz, 2H), 4.16(d, J = 9.2 Hz, 2H), 1.46(s, 9H). 
 
1-Boc-3-(4-chlorophenyl)-3-azetidinol (31b) 
General Procedure A. The azetidinol was obtained as a pale yellow solid (86%) mp 139.0-
140.6 oC; 1H NMR (400MHz, CDCl3): δ 7.4-7.38(m, 2H), 7.28(d, J = 8.8 Hz, 2H), 4.63(s, 1H), 
4.13-4.05(m, 4H), 1.39(s, 9H). 
 
1-Boc-3-(4-fluorophenyl)-3-azetidinol (31d) 
General Procedure A. The azetidinol was obtained as a pale yellow solid (64%); mp 90.8 - 
92.8 oC; 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.34 (m, 2H), 7.04 – 6.88 (m, 2H), 4.81 (s, 1H), 
4.08 (t, J = 5.8 Hz, 4H), 1.44 – 1.31 (m, 9H). 
 
General Procedure B: Formation of 3-Phenyl-3-aryl-heterocycles  
 Aluminum chloride (3.5 equiv.) placed in an ice bath and suspended in benzene (1.5 
mL). N-protected-aryl-heterocycle secondary alcohols (28, 77, 81 or 85) were separately 
dissolved in benzene (1.5mL) and added to the suspended aluminum chloride. The mixture 
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was stirred at 0 oC under argon for 2 hours. The reaction was then quenched with 0.1g of 
ice and allowed to stir for 30 minutes. Saturated sodium bicarbonate (3mL) was then 
added to the mixture followed by ammonium hydroxide to achieve a pH of 11. The mixture 
was then extracted with DCM (3 x 5 mL), washed with brine (2 x 5 mL) and dried over 
anhydrous sodium sulfate. The solvent was removed under reduced pressure. The mixture 
was then re-dissolved in a minimal amount of diethyl ether, and in a separate container 
oxalic acid (1.1 equiv.) is dissolved in a minimal amount if diethyl ether. The dissolved 
oxalic acid was then added drop-wise to the reaction mixture. The oxalate salts (73a, 74f, 
73k, 78a, 82a, and 86a) were immediately formed and collected by vacuum filtration.  
 
3,3-Diphenylazetidine oxalate salt (73a, ANT-243) 
General Procedure B. The azetidine was obtained as a white solid; mp 230.5-232.3 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.69 (s, 2H), 7.44 (d, J = 7.2 Hz, 4H), 7.34 (t, J = 6.9 Hz, 4H), 7.22 
(t, J = 6.6 Hz, 2H), 4.58 (s, 4H); 13C NMR (100 MHz, DMSO-d6) δ 146.0, 129.4, 127.5, 126.5, 
115.6, 75.8, 57.2, 55.9, 48.9. 
 
3-Phenyl-3-(4-chlorophenyl)-azetidine oxalate salt (73f, ANT-289) 
General Procedure B. The azetidine was obtained as a white solid; mp 214.6-217.6 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.51 - 7.26 (m, 8H), 7.24 (t, J = 6.6, 1H), 4.58 (s, 4H). 13C NMR (100 
MHz, DMSO-d6) δ 145.6, 144.9, 132.3, 129.5, 129.3, 128.6, 127.6, 126.5, 57.0, 48.6,   
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3-Phenyl-3-(4-fluorophenyl)-azetidine oxalate salt (73k, ANT-332) 
General Procedure B. The azetidine was obtained as a white solid; mp 164.2-166.4 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.51 – 7.40 (m, 4H), 7.35 (t, J = 7.5 Hz, 2H), 7.20 (dt, J = 17.5 Hz, J = 
7.9 Hz, 3H), 4.61 (s, 4H). 13C NMR (100 MHz, DMSO-d6) δ 164.4, 162.8, 160.4, 145.9, 142.2, 
142.2, 129.4, 128.8, 128.7, 127.5, 126.5, 126.2, 116.2, 116.0, 57.3, 48.7, 31.7.  
 
3,3-Diphenylpiperidine oxalate salt (78a, ANT-312)76 
General Procedure B. The piperidine was obtained as a white solid; mp 110.2 – 111.4 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 7.32 (dt, J = 15.3 Hz, J = 7.8 Hz, 8H), 7.17 (t, J = 
6.8 Hz, 2H), 2.97 (s, 4H), 2.60 (s, 4H). 13C NMR (100 MHz, DMSO-d6) δ 129.4, 127.0, 126.9, 
55.9, 43.9, 41.3, 32.1.  
 
3,3-Diphenylpyrrolidine oxalate salt (82a, ANT-339)70-75 
General Procedure B. The pyrrolidine was obtained as a white solid; mp 86.9 – 87.4 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.52 (s, 1H), 7.43 – 7.35 (m, 2H), 7.30 (t, J = 7.1 Hz, 4H), 7.19 
(dd, J = 7.9 Hz, J = 6.8 Hz, 4H), 3.93 (s, 2H), 3.16 (t, J = 6.7, 2H), 2.70 (t, J = 6.9, 2H). 13C 
NMR (100 MHz, DMSO-d6) δ 205.1, 204.8, 166.9, 163.2, 144.6, 129.3, 127.4, 127.2, 55.1, 53.7, 
44.2, 36.0.  
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3,3-Diphenyltropane oxalate salt (86a, ANT-325)76 
General Procedure B. The tropane was obtained as a white solid; mp 113.1-115.3 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.33 – 7.24 (m, 8H), 7.18 (td, J = 5.9 Hz, J = 2.9 Hz, 2H), 1.98 (s, 9H), 
1.76 (d, J = 11.1 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 164.6, 144.8, 129.1, 127.8, 127.2, 
115.6, 114.4, 55.1, 54.3, 46.4, 36.2, 33.5, 27.6, 26.5.  
 
 
General Procedure C: Formation of p-substituted Phenyl-aryl-heterocycle 
oxalate salt 
 Aluminum chloride (3.5 equiv.) placed in an ice bath and suspended in substituted-
benzene (1.5 mL). N-protected-aryl-heterocycle secondary alcohols (28, 77, 81 or 85) 
were separately dissolved in substituted-benzene (1.5mL) and added to the suspended 
aluminum chloride. The mixture was stirred at 0 oC under argon for 2 hours. The reaction 
was then quenched with 0.1g of ice and allowed to stir for 30 minutes. Saturated sodium 
bicarbonate (3mL) was then added to the mixture followed by ammonium hydroxide to 
achieve a pH of 11. The mixture was then extracted with DCM (3 x 5 mL), washed with 
brine (2 x 5 mL) and dried over anhydrous sodium sulfate. The solvent was removed under 
reduced pressure. The mixture was then re-dissolved in a minimal amount of diethyl ether, 
and in a separate container oxalic acid (1.1 equiv.) is dissolved in a minimal amount if 
diethyl ether. The dissolved oxalic acid was then added drop-wise to the reaction mixture. 
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The oxalate salts (73b-e, 74g-j, 73l-o, 78b-d, 82b-d, and 86b-d) were immediately formed 
and collected by vacuum filtration. 
 
3-(4-Chlorophenyl)-3-phenyl-azetidine oxalate salt (73b, ANT-267) 
General Procedure C. The azetidine was obtained as a white solid; mp 210.4-212.1 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.81 (s, 2H), 7.54 – 7.32 (m, 8H), 7.24 (t, J = 7.0 Hz, 1H), 4.58 (s, 
4H); 13C NMR (100 MHz, DMSO-d6) δ 145.6, 144.9, 132.3, 129.5, 129.3, 128.6, 127.6, 126.5, 
57.0, 48.6.  
 
3-(4-Fluorophenyl)-3-phenyl-azetidine oxalate salt (73c, ANT-268) 
General Procedure C. The azetidine was obtained as a white solid; mp 221.4-223.8 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.84 (s, 2H), 7.55 – 7.41 (m, 4H), 7.35 (t, J = 7.2 Hz, 2H), 7.22 
(dt, J = 17.1 Hz, 7.6 Hz, 3H), 4.76 – 4.44 (m, 4H). 13C NMR (100 MHz, DMSO-d6) δ 162.8, 
160.4, 145.9, 142.2, 129.4, 128.8, 128.8, 127.6, 116.2, 116.0, 75.8, 57.2, 56.2, 48.5, 46.2.  
 
3-(4-Methylphenyl)-3-phenyl-azetidine oxalate salt (73d, ANT-330) 
General Procedure C. The product was obtained as a white solid; mp 185.6-187.6 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.40 (d, J = 7.8 Hz, 11H), 7.36 – 7.27 (m, 4H), 7.21 (t, J = 7.2 Hz, 1H), 
7.14 (d, J = 7.9 Hz, 2H), 4.58 (s, 4H), 2.23 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 165.3, 
146.2, 143.1, 136.7, 129.9, 129.3, 127.4, 126.4, 115.6, 57.3, 48.9, 21.1.  
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3-(4-Methoxyphenyl)-3-phenyl-azetidine oxalate salt (73e, ANT-331) 
General Procedure C. The azetidine was obtained as a white solid; mp 160.0-162.8 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.40 – 7.21 (m, 7H), 6.89 (d, J = 8.6 Hz, 2H), 4.64 – 4.52 (m, 4H), 3.70 
(s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 165.1, 158.6, 146.4, 137.9, 127.8, 127.3, 126.8, 
126.4, 121.4, 116.5, 114.7, 57.3, 56.6, 55.9, 55.8, 48.6, 31.3.  
 
3-(4-Chlorophenyl)-3-(4-chlorophenyl)-azetidine oxalate salt (73g, ANT-290) 
General Procedure C. The azetidine was obtained as a white solid; mp 219.6-221.1 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 9.63 (s, 1H), 7.47 (d, J = 8.1 Hz, 4H), 7.41 (d, J = 7.9 Hz, 4H), 4.54 (s, 
4H).13C NMR (100 MHz, DMSO-d6) δ 144.5, 135.5, 132.4, 129.4, 128.6, 56.9, 48.3.  
 
3-(4-Fluorophenyl)-3-(4-chlorophenyl)-azetidine oxalate salt (73h, ANT-318) 
General Procedure C. The azetidine was obtained as a white solid; mp 170.9-172.9 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.49 – 7.41 (m, 6H), 7.18 (t, J = 8.8 Hz, 2H), 4.72 – 4.48 (m, 4H). 13C 
NMR (100 MHz, DMSO-d6) δ 165.4, 162.9, 160.5, 144.8, 141.8, 135.5, 132.3, 129.3, 128.8, 
128.7, 128.6, 116.3, 116.1, 99.0, 90.2, 57.1, 48.4.  
 
3-(4-Methylphenyl)-3-(4-chlorophenyl)-azetidine oxalate salt (73i, ANT-291) 
General Procedure C. The azetidine was obtained as a white solid; mp 203.4-204.6 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.42 (dd, J = 20.8 Hz, J = 7.4 Hz, 4H), 7.29 (d, J = 7.1 Hz, 
 126
2H), 7.15 (d, J = 7.0 Hz, 2H), 4.54 (s, 4H), 2.23 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 
145.1, 142.6, 136.9, 132.2, 130.0, 129.2, 128.6, 126.4, 57.1, 48.3, 21.2.  
 
3-(4-Methoxyphenyl)-3-(4-chlorophenyl)-azetidine oxalate salt (73j, ANT-319) 
General Procedure C. The azetidine was obtained as a white solid; mp 155.7-159.8 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.41 (q, J = 8.7 Hz, 4H), 7.32 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 
2H), 4.55 (s, 4H), 3.70 (d, J = 3.9 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 165.5, 158.8, 
145.3, 137.5, 132.1, 129.2, 128.9, 128.5, 127.8, 114.8, 99.0, 94.6, 85.9, 75.8, 57.2, 55.8, 48.3.  
 
3-(4-Chlorophenyl)-3-(4-fluorophenyl)-azetidine oxalate salt (73l, ANT-333) 
General Procedure C. The azetidine was obtained as a white solid; mp 166.1-168.2 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.52 – 7.44 (m, 4H), 7.40 (d, J = 8.6 Hz, 2H), 7.17 (t, J = 8.8 Hz, 2H), 
4.58 (s, 4H). 13C NMR (100 MHz, DMSO-d6) δ 165.4, 162.9, 160.4, 144.9, 141.8, 132.3, 129.3, 
128.8, 128.7, 128.6, 116.3, 116.1, 95.7, 75.8, 57.0, 48.4.  
 
3-(4-Fluorophenyl)-3-(4-fluorophenyl)-azetidine oxalate salt (73m, ANT-293) 
General Procedure C. The azetidine was obtained as a white solid; mp 212.9-214.4 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 9.52 (s, 1H), 7.48 (dd, J = 8.3 Hz, J = 5.6 Hz, 4H), 7.19 (t, J = 8.8 Hz, 
4H), 4.55 (s, 4H). 13C NMR (100 MHz, DMSO-d6) δ 162.9, 160.4, 155.4, 142.1, 128.8, 128.7, 
116.3, 116.1, 57.3, 48.1.  
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3-(4-Methylphenyl)-3-(4-fluorophenyl)-azetidine oxalate salt (73n, ANT-313) 
General Procedure C. The azetidine was obtained as a white solid; mp 161.4-163.3 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.46 (dd, J = 8.4 Hz, J = 5.4 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.21 – 
7.12 (m, 4H), 4.53 (s, 4H), 2.23 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 160.4, 142.9, 142.4, 
136.8, 129.9, 128.8, 128.7, 126.4, 116.2, 115.9, 115., 57.2, 48.2, 21.2.  
 
3-(4-Methoxyphenyl)-3-(4-fluorophenyl)-azetidine oxalate salt (73o, ANT-334) 
General Procedure C. The azetidine was obtained as a white solid; mp 150.6-151.8 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 7.43 (dt, J = 12.4 Hz, J = 6.2 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H), 7.17 (t, 
J = 8.8 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 4.68 – 4.44 (m, 4H), 3.71 (s, 3H). 13C NMR (100 MHz, 
DMSO-d6) δ 165.2, 158.7, 142.5, 137.8, 128.7, 128.6, 127.8, 116.1, 115.9, 114.8, 99.0, 65.6, 
57.4, 55.8, 48.2, 31.4.  
 
3-(4-Chlorophenyl)-3-phenyl-piperidine oxalate salt (78b, ANT-320) 
General Procedure C. The piperidine was obtained as a white solid; mp 112.0 – 113.7 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 7.60 – 7.04 (m, 9H), 2.98 (s, 2H), 2.54 – 2.38 (m, 6H). 13C NMR 
(100 MHz, DMSO-d6) δ 172.0, 164.8, 162.9, 150.0, 129.3, 123.9, 122.2, 120.7, 115.6, 90.2, 75.8, 
70.2, 25.1.   
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3-(4-Methoxyphenyl)-3-phenyl-piperidine oxalate salt (78c, ANT-329) 
General Procedure C. The piperidine was obtained as a white solid; mp 171.8-173.3 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.34 – 7.12 (m, 7H), 6.86 (d, J = 8.5 Hz, 2H), 3.80 – 
3.61 (m, 3H), 2.98 (s, 4H), 2.54 - 2.48 (m, 4H). 13C NMR (100 MHz, DMSO-d6) δ 165.0, 158.1, 
129.3, 128.3, 126.9, 126.7, 116.6, 114.7, 55.7, 43.3, 41.3, 32.5.  
 
3-(4-Methylphenyl)-3-phenyl-piperidine oxalate salt (78d, ANT-321) 
General Procedure C. The piperidine was obtained as a white solid; mp 120.1-121.5 oC; 1H 
NMR (400 MHz, DMSO-D6) δ 9.00 (s, 1H), 7.22 - 6.96 (m, 9H), 2.98 (s, 2H), 2.53 (d, J = 3.6 
Hz, 4H), 2.25 (s, 3H), 2.21 (s, 2H). 13C NMR (100 MHz, DMSO-D6) δ 164.2, 155.4, 138.4, 
123.0, 129.8, 129.3, 127.5, 126.9, 124.1, 115.6, 44.2, 43.4, 41.3, 32.3, 30.2, 21.9, 21.1.  
 
3-(4-Chlorophenyl)-3-phenyl-pyrrolidine oxalate salt (82b, ANT-340) 
General Procedure C. The pyrrolidine was obtained as a white solid; mp 126.5 - 128.0 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 7.41 – 7.06 (m, 9H), 4.47 - 4.14 (m, 1H), 3.85 - 3.79 (m, 1H), 
3.56 – 3.29 (m, 1H), 2.72 – 2.56 (m, 1H), 2.34 – 2.08 (m, 1H), 1.68 (s, 1H). 13C NMR (100 
MHz, DMSO-d6) δ 196.3, 165.1, 165.1, 155.4, 130.4, 128.9, 128.4, 127.8, 116.6, 115.5, 115.6, 
76.4, 75.8.  
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3-(4-Methoxyphenyl)-3-phenyl-pyrrolidine oxalate salt (82c, ANT-341) 
General Procedure C. The pyrrolidine was obtained as a white solid; mp 115.1 – 118.8 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.64 (s, 1H), 7.38 – 7.20 (m, 7H), 6.89 – 6.79 (m, 2H), 3.90 - 3.81 
(m, 2H), 3.66 (s, 4H), 3.12 (s, 2H), 2.75 – 2.56 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 
175.3, 172.1, 142.5, 140.2, 137.5, 129.2, 128.4, 127.1, 114.5, 113.2, 111.4, 110.2, 110.0, 75.8, 
55.7.  
 
3-(4-Methylphenyl)-3-phenyl-pyrrolidine oxalate salt (82d, ANT-342) 
General Procedure C. The pyrrolidine was obtained as a white solid; mp 133.5 – 135.2 oC; 1H 
NMR (400 MHz, DMSO-d6) δ 9.58 (s, 1H), 7.38 (t, J = 8.3, 1H), 7.31 – 7.26 (m, 2H), 7.16 (d, J 
= 6.3 Hz, 4H), 7.10 (d, J = 7.5, 1H), 7.00 (s, 1H), 3.89 (d, J = 11.2 Hz, 2H), 3.14 (s, 2H), 2.67 
(dd, J = 15.3 Hz, 7.1 Hz, 2H), 2.24 (d, J = 1.7 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 163.5, 
135.5, 129.8, 129.2, 127.7, 127.0, 124.2, 95.7, 94.5, 90.2, 44.1, 36.1, 21.8, 21.1.  
 
3-(4-Chlorophenyl)-3-phenyl-tropane oxalate salt (86b, ANT-326) 
General Procedure C. The tropane was obtained as an orange oil; 1H NMR (400 MHz, DMSO-
d6) δ 9.04 (s, 1H), 7.92 – 6.96 (m, 9H), 1.98 - 1.94 (m, 8H), 1.76 (d, J = 8.1 Hz, 2H). 13C NMR 
(100 MHz, DMSO-d6) δ 164.6, 144.7, 131.0, 129.2, 129.1, 128.6, 127.9, 127.7, 127.2, 115.6, 
55.9, 55.2, 36.2, 33.4, 26.5. 
 
 130
3-(4-Methylphenyl)-3-phenyl-tropane oxalate salt (86d, ANT-328) 
General Procedure C. The tropane was obtained as a white solid; mp 132.3-133.8 oC; 1H NMR 
(400 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.33 – 6.99 (m, 9H), 3.07 (d, J = 6.0 Hz, 3H), 2.04 – 1.88 
(m, 8H), 1.80 - 1.77 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 162.1, 131.7, 131.6, 131.1, 
129.7, 129.2, 128.7, 128.6, 127.7, 127.3, 127.2, 114.4, 55.3, 30.2.   
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Appendix I 
List of abbreviations 
 METH – Methamphetamine 
 DAT – Dopamine transporter 
 SERT – Serotonin transporter 
 NET – Norepinephrine transporter 
 IC50 – Half maximal inhibitory concentration 
 Ki – Inhibition constant 
 SSRI – Serotonin selective re-uptake inhibitor 
 SNRI – Serotonin/Norepinephrine re-uptake inhibitor 
cLogP – Calculated lipophilicity 
 EtOAc – Ethyl acetate 
 DI – Deionized water 
 DCM – dichloromethane 
NH4Cl – Ammonium chloride 
THF – Tetrahydrofuran 
LAH – Lithium aluminum hydride 
TFA – Trifluoroacetic acid 
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Appendix II 
 
 
 
Table 1:Crystal data and structure refinement for ANT-35. 
Identification code  chem6316_3rd_0m 
Empirical formula  C16 H18 Cl N O 
Formula weight  275.76 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 6.8088(5) Å a= 90°. 
 b = 28.044(2) Å b= 93.7900(10)°. 
 c = 7.9142(6) Å g = 90°. 
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Volume 1507.9(2) Å3 
Z 4 
Density (calculated) 1.215 Mg/m3 
Absorption coefficient 0.245 mm-1 
F(000) 584 
Crystal size ? x ? x ? mm3 
Theta range for data collection 2.68 to 22.50°. 
Index ranges -7<=h<=7, -30<=k<=30, -8<=l<=8 
Reflections collected 14081 
Independent reflections 1980 [R(int) = 0.0256] 
Completeness to theta = 22.50° 99.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1980 / 0 / 244 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0284, wR2 = 0.0693 
R indices (all data) R1 = 0.0416, wR2 = 0.0745 
Largest diff. peak and hole 0.155 and -0.141 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for ANT-1.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Cl(1) 1021(1) 2458(1) 5627(1) 66(1) 
N(2) -2586(3) 2881(1) 7179(2) 61(1) 
C(3) -4126(4) 3027(1) 5837(3) 61(1) 
C(4) -3379(3) 3546(1) 5963(2) 46(1) 
O(5) -1988(2) 3647(1) 4746(1) 49(1) 
C(5) -2150(4) 3394(1) 7568(3) 57(1) 
C(7) -2792(3) 3706(1) 3033(2) 58(1) 
C(8) -1074(3) 3782(1) 1977(2) 50(1) 
C(9) -810(4) 4207(1) 1163(3) 70(1) 
C(10) 805(5) 4284(1) 248(3) 86(1) 
C(11) 2174(4) 3931(1) 137(3) 79(1) 
C(12) 1932(3) 3503(1) 913(3) 72(1) 
C(13) 301(3) 3428(1) 1831(3) 60(1) 
C(14) -4809(3) 3950(1) 6121(2) 45(1) 
C(15) -6758(3) 3924(1) 5525(2) 56(1) 
C(16) -7981(4) 4314(1) 5618(3) 65(1) 
C(17) -7281(4) 4728(1) 6324(3) 68(1) 
C(18) -5360(4) 4761(1) 6948(3) 68(1) 
C(19) -4123(3) 4375(1) 6840(3) 57(1) 
________________________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for  ANT-1. 
_____________________________________________________  
N(2)-C(5)  1.496(3) 
N(2)-C(3)  1.500(3) 
C(3)-C(4)  1.544(3) 
C(4)-O(5)  1.423(2) 
C(4)-C(14)  1.504(3) 
C(4)-C(5)  1.535(3) 
O(5)-C(7)  1.438(2) 
C(7)-C(8)  1.497(3) 
C(8)-C(9)  1.372(3) 
C(8)-C(13)  1.376(3) 
C(9)-C(10)  1.373(3) 
C(10)-C(11)  1.367(4) 
C(11)-C(12)  1.364(4) 
C(12)-C(13)  1.382(3) 
C(14)-C(15)  1.381(3) 
C(14)-C(19)  1.387(3) 
C(15)-C(16)  1.379(3) 
C(16)-C(17)  1.362(3) 
C(17)-C(18)  1.370(3) 
C(18)-C(19)  1.379(3) 
 
C(5)-N(2)-C(3) 90.17(15) 
N(2)-C(3)-C(4) 90.01(15) 
O(5)-C(4)-C(14) 111.74(14) 
O(5)-C(4)-C(5) 105.32(15) 
C(14)-C(4)-C(5) 117.51(15) 
O(5)-C(4)-C(3) 111.99(15) 
C(14)-C(4)-C(3) 120.22(16) 
C(5)-C(4)-C(3) 87.12(15) 
C(4)-O(5)-C(7) 115.60(14) 
N(2)-C(5)-C(4) 90.46(15) 
O(5)-C(7)-C(8) 106.27(16) 
C(9)-C(8)-C(13) 118.5(2) 
C(9)-C(8)-C(7) 121.1(2) 
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C(13)-C(8)-C(7) 120.38(19) 
C(8)-C(9)-C(10) 121.2(2) 
C(11)-C(10)-C(9) 119.5(2) 
C(12)-C(11)-C(10) 120.4(2) 
C(11)-C(12)-C(13) 119.8(2) 
C(8)-C(13)-C(12) 120.5(2) 
C(15)-C(14)-C(19) 118.40(19) 
C(15)-C(14)-C(4) 123.02(17) 
C(19)-C(14)-C(4) 118.53(17) 
C(16)-C(15)-C(14) 120.7(2) 
C(17)-C(16)-C(15) 120.1(2) 
C(16)-C(17)-C(18) 120.3(2) 
C(17)-C(18)-C(19) 119.8(2) 
C(18)-C(19)-C(14) 120.6(2) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for ANT-1.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Cl(1) 61(1)  71(1) 69(1)  -9(1) 23(1)  4(1) 
N(2) 68(1)  56(1) 61(1)  9(1) 26(1)  6(1) 
C(3) 60(1)  56(1) 67(2)  -7(1) 15(1)  -9(1) 
C(4) 48(1)  52(1) 39(1)  -3(1) 12(1)  -9(1) 
O(5) 46(1)  66(1) 36(1)  -1(1) 8(1)  -6(1) 
C(5) 62(2)  64(1) 45(1)  3(1) 10(1)  -2(1) 
C(7) 56(1)  81(2) 39(1)  -2(1) 6(1)  2(1) 
C(8) 58(1)  61(1) 32(1)  -4(1) 7(1)  0(1) 
C(9) 99(2)  62(1) 52(1)  -2(1) 23(1)  10(1) 
C(10) 124(2)  70(2) 69(2)  4(1) 38(2)  -10(2) 
C(11) 79(2)  109(2) 52(1)  0(1) 25(1)  -22(2) 
C(12) 61(2)  99(2) 56(1)  0(1) 13(1)  16(1) 
C(13) 63(1)  69(2) 50(1)  10(1) 8(1)  7(1) 
C(14) 52(1)  50(1) 34(1)  -1(1) 12(1)  -6(1) 
C(15) 57(1)  63(1) 50(1)  -9(1) 7(1)  -6(1) 
C(16) 58(2)  80(2) 57(1)  -2(1) 7(1)  6(1) 
C(17) 77(2)  66(2) 63(1)  3(1) 17(1)  13(1) 
C(18) 86(2)  49(1) 70(2)  -7(1) 14(1)  -6(1) 
C(19) 57(1)  57(1) 58(1)  -2(1) 7(1)  -9(1) 
______________________________________________________________________________ 
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for ANT-1. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2B) -3000(30) 2721(8) 8140(30) 84(7) 
H(2A) -1440(40) 2710(9) 6740(30) 102(8) 
H(3B) -4000(30) 2872(7) 4810(30) 67(6) 
H(3A) -5390(30) 2974(7) 6260(30) 73(6) 
H(5B) -2730(30) 3487(7) 8640(30) 66(6) 
H(5A) -800(30) 3467(7) 7580(20) 59(6) 
H(7B) -3720(30) 3977(7) 2980(20) 70(6) 
H(7A) -3480(30) 3410(7) 2740(30) 65(6) 
H(9) -1800(30) 4444(8) 1230(30) 81(7) 
H(10) 980(40) 4600(11) -290(40) 122(10) 
H(11) 3220(40) 3993(9) -460(30) 96(8) 
H(12) 2840(40) 3257(9) 790(30) 94(8) 
H(13) 100(30) 3133(8) 2370(30) 74(7) 
H(15) -7220(30) 3641(7) 5080(20) 57(6) 
H(16) -9330(30) 4285(7) 5200(30) 74(7) 
H(17) -8100(30) 4995(8) 6380(30) 79(7) 
H(18) -4830(30) 5041(8) 7400(30) 76(7) 
H(19) -2790(30) 4393(6) 7250(20) 55(6) 
________________________________________________________________________________ 
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 Table 6.  Torsion angles [°] for ANT-1. 
________________________________________________________________  
C(5)-N(2)-C(3)-C(4) 11.42(17) 
N(2)-C(3)-C(4)-O(5) 94.22(17) 
N(2)-C(3)-C(4)-C(14) -131.54(17) 
N(2)-C(3)-C(4)-C(5) -11.15(16) 
C(14)-C(4)-O(5)-C(7) -63.3(2) 
C(5)-C(4)-O(5)-C(7) 168.03(17) 
C(3)-C(4)-O(5)-C(7) 74.9(2) 
C(3)-N(2)-C(5)-C(4) -11.49(17) 
O(5)-C(4)-C(5)-N(2) -100.86(16) 
C(14)-C(4)-C(5)-N(2) 133.99(16) 
C(3)-C(4)-C(5)-N(2) 11.17(16) 
C(4)-O(5)-C(7)-C(8) -177.05(16) 
O(5)-C(7)-C(8)-C(9) -114.7(2) 
O(5)-C(7)-C(8)-C(13) 63.9(2) 
C(13)-C(8)-C(9)-C(10) -1.2(3) 
C(7)-C(8)-C(9)-C(10) 177.4(2) 
C(8)-C(9)-C(10)-C(11) 0.2(4) 
C(9)-C(10)-C(11)-C(12) 0.7(4) 
C(10)-C(11)-C(12)-C(13) -0.6(4) 
C(9)-C(8)-C(13)-C(12) 1.3(3) 
C(7)-C(8)-C(13)-C(12) -177.35(19) 
C(11)-C(12)-C(13)-C(8) -0.4(3) 
O(5)-C(4)-C(14)-C(15) 108.36(19) 
C(5)-C(4)-C(14)-C(15) -129.73(19) 
C(3)-C(4)-C(14)-C(15) -26.0(3) 
O(5)-C(4)-C(14)-C(19) -69.1(2) 
C(5)-C(4)-C(14)-C(19) 52.8(2) 
C(3)-C(4)-C(14)-C(19) 156.57(18) 
C(19)-C(14)-C(15)-C(16) 1.1(3) 
C(4)-C(14)-C(15)-C(16) -176.39(18) 
C(14)-C(15)-C(16)-C(17) -0.9(3) 
C(15)-C(16)-C(17)-C(18) -0.1(3) 
C(16)-C(17)-C(18)-C(19) 0.9(3) 
C(17)-C(18)-C(19)-C(14) -0.7(3) 
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C(15)-C(14)-C(19)-C(18) -0.3(3) 
C(4)-C(14)-C(19)-C(18) 177.30(18) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table 7.  Hydrogen bonds for ANT-1  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(2)-H(2A)...Cl(1) 1.00(3) 2.07(3) 3.058(2) 171(2) 
 N(2)-H(2B)...Cl(1)#1 0.94(2) 2.18(3) 3.097(2) 164.6(19) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1/2,-y+1/2,z+1/2       
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